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OBJECTIVES. Purpose of this retrospective, register-based pharmacoepidemiologic study was to 
analyse post-discharge purchases of drugs with an actionable pharmacogenetics-based 
prescribing guideline with a patient cohort consisting of Finnish hospital patients.  
 
MATERIALS. Altogether 33 eligible actionable drugs were identified from prescribing guidelines 
compiled by the Clinical Pharmacogenetics Implementation Consortium. Hospital admission data, 
drug purchase data, and mortality data were utilized from 1.42 million eligible patients. 
 
METHODS. Each patient was followed from the first hospital admission to either surgical or internal 
medicine unit until the end of year 2016 or until death. Statistical analyses were descriptive on 
prevalence and incidence of drug purchases of individual drugs and related genes. Impact in 
Finnish population was studied by combining Finnish phenotype frequencies with drug incidence 
data. Differences in post-discharge drug purchases between the units was studied with Cox 
proportional-hazards model.  
 
RESULTS. Genes related to study drugs consisted of five drug-metabolizing CYP-genes, four other 
pharmacokinetic genes, one gene encoding a pharmacological drug target and three HLA-alleles 
altering to susceptibility to adverse effects. Most frequently purchased drugs in 2-year follow-up 
included common analgesics, proton pump inhibitors, cardiovascular drugs and a selective 
serotonin reuptake inhibitor. In 2-year follow-up, 60% of the patients purchased at least one drug, 
and drug purchases of 22% of the patients were associated to ≥ 2 different genes.  
 
DISCUSSION. Results provide significant new information of drug initiations in hospital discharged 
patients, which can be utilized in targeting pre-emptive pharmacogenetics testing to prevent drug 
adverse effects and rehospitalization.  However, more studies are required on cost-effectiveness 
of pharmacogenetic testing. 
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1.1 Defining pharmacogenetics 
 
Primarily, pharmacogenetics (PGt) is a research area that studies how variations in individual 
genotype affect drug response, metabolism and risk for adverse drug effects (Niemi, 2016). After 
establishment in the end of the 1950’s, pharmacogenetics has relatively recently become a more 
popular research area aiming to improve individual drug therapy by utilizing human genomic data. 
Advancements in gene cloning and techniques in DNA genotyping and sequencing have 
accelerated understanding of the interplay between genetics and individual drug response (Daly, 
2017; Lunenburg et al., 2020).  
To be precise with the study area terminology, the ICH guideline E15 defines pharmacogenetics 
(PGt) as a subset of pharmacogenomics, which studies the variations in DNA sequence related to 
drug response. Pharmacogenomics (PGx) studies the variations in DNA and RNA characteristics 
related to drug response. (https://database.ich.org/sites/default/files/E15_Guideline.pdf) Both 
terms and the abbreviation PGx are often used interchangeably. (Daly, 2017) Pharmacogene is a 
term referring to pharmacogenetically relevant genes, which can code drug transporters, drug 
metabolizing enzymes or drug targets. Particular human leukocyte antigen (HLA) alleles in major 
histocompatibility complex are also pharmacogenes. 
(https://www.pharmgkb.org/page/typesOfPgx; https://www.pharmvar.org/) 
High variation has been found in drug response between individuals, and according to Zhou et al, 
(2017) it is estimated that 40-70% of patients experience adverse drug reactions (ADR) or lack of 
efficacy of their medication. Genetic polymorphisms are estimated to cause 15-30% of variations 
in drug response (Zhou et al., 2017), and pharmacogenetics has been recognised to be a potential 
tool in personalized medicine. However, it is to be noted that there are also other factors affecting 
the drug response. Several intrinsic and extrinsic factors have an impact on individual drug 
metabolism and response, as well as the risk for adverse drug effects. All patient-specific factors 
should be considered when prescribing a drug. (Raunio and Huupponen, 2018; Niemi, 2016) The 





Figure 1. Factors affecting drug response 
 
Of the factors affecting drug response (Figure 1), genes affecting the drug response remain 
unchangeable during the lifetime, which support consideration of pharmacogenetic testing results 
in prescribing situations. However, it is to be noted that although the pharmacogenetic test result 
is permanent, the interpretation might change due to increased knowledge of the allele functions. 
Other factors represented in the Figure 1 are prone to change during the lifetime and their impact 
to pharmacotherapy must be evaluated repeatedly. 
 
1.2 Pharmacogenetic testing 
 
Pharmacogenetics is primarily utilized in personalized medicine to determine an appropriate drug 
dose, to identify patients predicted to have a low or no response to a drug and to recognize 
individuals at risk for serious drug-induced toxicities (Daly, 2017; Alshabeeb et al., 2019). Testing 
the allelic variation of relevant pharmacogenes can be either reactive (“as needed”) or pre-emptive. 
(Mukerjee et al., 2018) The impact of genetics in unexplained adverse drug reactions can be 
analysed with reactive testing. (Lunenburg et al., 2020) Reactive genetic testing is also required 
before initiating certain pharmacotherapies due to genetic predisposition to a risk for serious 
adverse drug reactions, such as testing the possible dihydropyrimidine dehydrogenase (DPD) 
deficiency before initiating fluorouracil treatment. 
(https://www.ema.europa.eu/en/medicines/human/referrals/fluorouracil-fluorouracil-related-




so that results are available for the future, and can be utilized for the rest of the patient’s life. 
(Mukerjee et al., 2018) The advantage of pre-emptive pharmacogenetic testing is the available test 
results at the point of prescribing, which facilitates selection of a drug and determining the most 
likely suitable dose. (Lunenburg et al., 2020; Mukerjee et al., 2018)  
In the pharmacogenetic testing, variations in gene regulatory regions or coding regions can be 
detected.  Variations in regulatory regions of the gene affect the level of expression, while variations 
in the coding region affect the gene function, which both might lead to altered drug exposure, high 
concentration of toxic metabolites, altered interactions with drug targets or idiosyncratic drug 
toxicity due to activation of the immune system. (Mukerjee et al., 2018) 
In choosing a relevant pharmacogenetic assay, sensitivity and specificity of the test should be 
evaluated in addition to the target population, possible earlier conducted genotyping, technical 
requirements and costs. (Mukerjee et al., 2018) Several approaches can be utilized in 
pharmacogenetic testing, in which either preselected variants are probed with well-defined drug-
gene interactions or a panel of well-studied pharmacokinetic and pharmacodynamic markers of 
relevant drug metabolizing enzymes, drug transporters, receptors and various other genes 
associated to drug response is chosen. (Mukerjee et al., 2018) Most importantly, the assay chosen 
should detect variants, which are common in the population to be genotyped. For example, high 
variation in allele frequencies associated with anticoagulant warfarin response has been detected 
between different ethnicities. (Mukerjee et al., 2018; Kimmel et al., 2013; Limdi et al., 2015; 
Wadelius et al., 2009) Patients of Caucasian origin carry reduced function alleles CYP2C9*2 and 
CYP2C9*3 more often than African-Americans. Carriers of these alleles have an increased risk for 
bleeding due to warfarin therapy and they require lower warfarin doses. However, other reduced 
function alleles CYP2C9*5, *6*, *8 and *11 are more common in African-Americans. Ethnic 
differences were observed in various studies on warfarin dosing algorithms and ethnicity influences 
to warfarin dosing, which have led to current recommendation of utilizing warfarin dosing algorithms 
stratified by race. (Kimmel et al., 2013; Limdi et al., 2015; Johnson et al., 2017; Wadelius et al., 
2009) Moreover, a broad implementation of pharmacogenetics requires strategies also for 
detecting and interpreting rare variants. (McInnes et al., 2020) However, technical requirements 
and exact genotyping assay composition are outside the scope of this study. 
Although some dose adjustments based on PGx test results are justified even after drug initiation, 
it is recognised that testing a patient already exposed to a possible drug-gene interaction is not that 
beneficial, which strongly supports pre-emptive testing to be conducted before initiating drugs with 




tool when optimizing prescribing, dose determination and patient monitoring. (Westergaard et al., 
2020; Lunenburg et al., 2020)  
 
1.3 Relevant pharmacogenes 
 
In general, pharmacogenes, genes affecting the drug response represent four different types of 
genes, which are illustrated in the Figure 2 below.   
 
Figure 2. Genes affecting drug response  
 
Pharmacokinetic genes encode proteins that affect the absorption, distribution, metabolism and 
excretion of the drugs. These cell membrane transport proteins and enzymes catalyse the drug 
metabolism phases I and II occurring mainly in liver. Pharmacodynamic genes encode receptors 
and other proteins targeted by drugs, and affect the interaction of the drug with the body. Genes 
altering the patient to a greater risk for adverse drug reaction are usually related to immunological 
reactions. Generally, these adverse effects are rare but when occurring, even fatal, and are not 
dependent on pharmacologic response or the drug dose. Genes such as HER2 and CFTR 
associated with the disease risk and progression are outside of the scope of this study. In general, 
they are important factors e.g., in drug selection for a cancer patient. (Niemi, 2016)  
It has been showed in a study combining electronic medical records with exome sequencing results 
of hospitalized patients that the number of pharmacogenetic variants correlates with the mean 




their genome, the longer was the hospital period. (Finkelstein et al., 2020) Comprehensive and 
routinely conducted PGx test panels would potentially reduce health care costs by decreasing drug-
related adverse events, insufficient treatment responses and re-hospitalization of the polypharmacy 
patients. (Westergaard et al., 2020; Lunenburg et al., 2020).  
Even up to 95% of the population is thought to have at least one clinically relevant pharmacogenetic 
variant in their genome (van der Wouden, C. H. et al., 2017; Tarkiainen et al., 2021), which is 
defined as an actionable genotype in pharmacogenetic terminology. An actionable genotype refers 
to a patient’s unique genotype associated with increased risk of lack of efficacy or adverse drug 
reactions. A patient having an actionable genotype might require either dose increase or decrease 
of a drug or the drug in question should be avoided. (https://cpicpgx.org/) 
In the context of drug metabolism, the variant alleles have a functional status ranging from no 
function to increased function, which impacts the associated phenotype ranging from ultrarapid 
metabolizer (UM) to poor metabolizer (PM). Other distinctive phenotypes are rapid metabolizer 
(RM), normal metabolizer (NM, previously known as extensive metabolizer, EM) and intermediate 
metabolizer (IM). The functional status is determined by scoring the metabolic activity of the alleles. 
(Tornio and Backman, 2018; Westergaard et al., 2020) Polymorphism occurring in phase I drug 
metabolizing enzymes has been recognised to increase the risk for ADRs. (Zhou et al., 2017) 
Genotype associated with a phenotype of poor metabolizer generally leads to insufficient drug 
metabolism due to lack of metabolizing enzyme, which increases the drug concentration and 
altering the patient to ADRs more likely. In case the patient has rapid or ultrarapid metabolizer 
phenotype, the drug concentration might not reach the therapeutic level leading to insufficient 
treatment response (Tarkiainen et al., 2021).  
For pharmacodynamic genes, phenotypes range from increased activity to poor activity based on 
allele functional status. For genes associated with high risk for adverse drug reactions, phenotypes 
of positive or negative are used in which a patient is either a homozygous or heterozygous allele 
positive or any copies of the allele is not detected. (Caudle et al., 2017)  
A star (*) allele nomenclature has been agreed to define the different variants of the genes. A 
database managed by the Pharmacogene Variation Consortium (PharmVar) includes the identified 
variants of the Cytochrome P450-genes and some other relevant pharmacogenes 
(https://www.pharmvar.org/)  
In pharmacogenetic literature and test reporting the use of terms has been variable and a need for 
standardized, consistent PGx terms has been recognized. One standardization project was 




pharmacogenetic experts and final terms were published in 2016. The terms agreed in the project 
are listed in the Table 1 with their respective functional definitions and genetic definitions. The CPIC 
recommends the terms to be widely used in all areas of pharmacogenetics, including the clinical 
decision support systems, PGx laboratory testing results and the prescribing recommendations. 
The name of the associated gene should be added to all terms to describe the association between 
the genotype and phenotype (e.g., CYP2C19 Normal metabolizer, SLCO1B1 Increased function, 
HLA-B allele positive) (Caudle et al., 2017) All possible phenotypes cannot be found in every CYP-
enzymes due to the nature of the function of identified alleles, e.g., phenotypes identified for 
CYP2C9 are normal, intermediate and poor but no alleles leading to CYP2C9 ultrarapid or rapid 
metabolism is known.   
Table 1. The final terms agreed in the term standardization project by CPIC for allele functional 
status and phenotypes 
TERM/GENE 
CATEGORY 





Increased function Function greater than normal 
function 
N/A 
 Normal function Fully functional/wild-type N/A 
 Decreased function Function less than normal 
function 
N/A 
 No function Non-functional N/A 
 Unknown function No literature describing 
function or the allele is novel 
N/A 
 Uncertain function Literature supporting function is 












Increased enzyme activity 
compared to rapid 
metabolizers 
Two increased function alleles, 
or more than 2 normal function 
alleles 
 Rapid metabolizer 
(RM) 
Increased enzyme activity 
compared to normal 
metabolizers but less than 
ultrarapid metabolizers 
Combinations of normal 







Fully functional enzyme activity Combinations of normal 




Decreased enzyme activity 
(activity between normal and 
poor metabolizer) 
Combinations of normal 
function, decreased function, 
and/or no function alleles 
 Poor metabolizer 
(PM) 
Little to no enzyme activity Combination of no function 





Increased function Increased transporter function 
compared to normal function. 
One or more increased function 
alleles 
 Normal function Fully functional transporter 
function 
Combinations of normal 
function and/ or decreased 
function alleles 
 Decreased function Decreased transporter function 
(function between normal and 
poor function) 
Combinations of normal 
function, decreased function, 
and/or no function alleles 
 Poor function Little to no transporter function Combination of no function 






Positive Detection of high-risk allele Homozygous or heterozygous 
for high-risk allele 
 Negative High-risk allele not detected No copies of high-risk allele 
The table has been partly adapted from Caudle et al., 2017. N/A = not applicable 
 
In translating genotype into a predicted phenotype, the Activity Score (AS) system can be utilized. 
Introduced by Gaedigk et al., in 2008, the AS system has become widely accepted and used in 
pharmacogenetics. Originally developed to describe the metabolic phenotype of CYP2D6, the AS 
is a quantitative value, which is based on the sum of the allele activity scores. The system gives 
each allele a value 0, 0.5 or 1, based on allele function activity. Value 0 refers to no function, and 
value 1 to normal function, while value 0.5 stands for decreased function. It is to be noticed that 
value 0.5 does not stand for 50% reduction in allele activity but a decreased functionality 
somewhere between no function and full function. In case the allele has two or more copies, the 
allele value (0, 0.5 or 1) is multiplied by the number of gene copies resulting in an AS value possible 
higher than 2. (Gaedigk et al., 2008; Gaedigk et al., 2018) In addition to CYP2D6, the AS system 




new information of allele functional status is gained and possible new alleles are found. 
(https://cpicpgx.org/) 
A drug-drug-gene interaction might lead to phenoconversion, a phenomenon in which a person 
with a NM or RM phenotype turns to PM due to concomitant medication altering the metabolizing 
status. Mismatches in genotype to phenotype interpretation might occur due to phenoconversion, 
which especially complicates the medication of polypharmacy patients. (Westergaard et al., 2020) 
 




Pharmacogenetics is highly defined by the genes encoding cytochrome P450 (CYP) drug 
metabolizing enzymes. Altogether 57 functional CYP-genes has been described in humans, and 
they have been categorized into 18 families and 44 subfamilies by their sequence similarity. Genes 
belonging to families 1-3 are responsible of coding enzymes, which metabolize majority (70-80%) 
of the hepatically cleared drugs, as the rest of the CYP-genes have a role in synthesis or 
metabolism of several endogenic compounds such as bile acids, eicosanoids and steroids. (Raunio 
and Huupponen, 2018; Tornio and Backman, 2018)  
CYP-enzymes catalyse oxidative biotransformation of the drugs converting them to either active 
substances or inactive metabolites. CYP-enzymes are unspecific and several structurally different 
compounds can act as a substrate, although a single CYP-enzyme is usually the predominant 
metabolizing pathway for many drugs. (Raunio and Huupponen, 2018; Tornio and Backman, 2018) 
Of the CYP-genes, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 shown polymorphism of major 
clinical significance. (Tornio and Backman, 2018)  
 
1.4.2. Other pharmacokinetic genes 
 
Clinically relevant genetic variation occurs in pharmacokinetic genes DPYD, SLCO1B1, TPMT, and 
NUDT15. Dihydropyrimidine dehydrogenase (DPD) protein encoded by gene DPYD is a phase I 
drug metabolizing enzyme and a rate-limiting factor in uracil and thymidine catabolism pathway. 
Cytostatic fluorouracil, capecitabine and tegafur belonging in the fluoropyrimide-group transform 
into inactive metabolites mainly via DPD-enzyme. Patients suffering from a rare genetic DPD-




associated drugs in chemotherapy. (Niemi, 2016; https://www.ncbi.nlm.nih.gov/gene/1806#gene-
expression; Wei et al., 1998) On April 2020 the European Medicines Agency (EMA) recommended 
(EMA/367286/2020) that all patients initiating cancer treatment with fluorouracil, capecitabine or 
tegafur should be pre-emptively tested for the lack of DPD-enzyme to ensure safety of the 
pharmacotherapy. (https://www.ema.europa.eu/en/medicines/human/referrals/fluorouracil-
fluorouracil-related-substances-capecitabine-tegafur-flucytosine-containing-medicinal) 
Organic anion transporting polypeptide 1B1 (OATP1B1), encoded by the gene SLCO1B1 is a liver-
specific transmembrane receptor protein, which mediates the Na-independent uptake of several 
different endogenous compounds, such as bilirubin (Niemi et al., 2011; Pasanen et al., 2006; The 
Search Collaborative Group, 2008). It also transports cholesterol-lowering statins and a number of 
other drugs from blood to liver hepatocytes. A common single nucleotide variant (c.521T>C, 
rs4149056) impairs the ability of OATP1B1 to transport statins into the liver, which causes 
especially high simvastatin concentrations in plasma and an increased risk for muscle-related 
symptoms, ranging from mild muscle pain to severe rhabdomyolysis. Due to marked increase of 
systemic simvastatin levels and a higher risk of muscle toxicity, these patients require either a lower 
simvastatin dose or another statin alternative. (Niemi, 2016; 
https://www.ncbi.nlm.nih.gov/gene/10599; 
https://www.ncbi.nlm.nih.gov/gtr/conditions/CN128903/; Pasanen et al., 2006; The Search 
Collaborative Group, 2008) 
Gene TPMT encodes thiopurine S-methyltransferase (TPMT) enzyme, which metabolizes 
chemotherapeutic thiopurine drugs, such as azathioprine, 6-mercaptopurine and thioguanine. 
Genetic variation affects the enzyme activity, which correlates interpatient differences in thiopurine 
drug sensitivity and toxicity. Patients heritably lacking the TPMT enzyme suffer from thiopurine S-
methyltransferase deficiency and are especially prone to develop bone marrow suppression when 
using thiopurine drugs in normal therapeutic doses. (Niemi, 2016; 
https://www.ncbi.nlm.nih.gov/gene/7172) 
Another factor regulating the thiopurine metabolism is nudix hydrolase 15 (NUDT15) enzyme 
encoded by gene NUDT15. The enzyme belongs to a superfamily of Nudix hydrolases, which 
catalyse the hydrolysis reactions of nucleoside diphosphates. Patients suffering from NUDT15 
deficiency due to having loss-of function variants of NUDT15 are prone to excessive DNA damage, 
bone marrow suppression and thiopurine-induced early leukopenia. 





1.4.3. Vitamin K epoxide reductase complex subunit 1 
 
The vitamin K epoxide reductase complex subunit 1 (VKORC-1) encodes the pharmacological drug 
target of anticoagulant warfarin. It participates to the vitamin K activation in the endoplasmic 
reticulum membrane, which is a crucial co-factor in blood-clotting enzyme formation. Generally, the 
significance of this type of genes affecting the drug response via drug targets is less known than 
the impact of pharmacokinetic genes. Genetic differences of the warfarin drug target VKORC-1 
have a considerable impact on the warfarin dose needed. A common single nucleotide variant with 
an allele frequency approximately 40% in patients with a European ancestry increases the 
anticoagulation effect of warfarin. Together with patient-specific factors such as age and weight, 
and CYP2C9, the other warfarin metabolism associated gene, the allelic variation of VKORC-1 
explains over 50% of the interpatient variation in warfarin dose. (Niemi, 2016; 




Variability in genes encoding the human leukocyte antigens type class I A or B (HLA-A and HLA-
B) of the major histocompatibility complex alter the patient to a risk for developing drug 
hypersensitivity syndromes with an immunological mechanism. Generally, these types of adverse 
effects are difficult to predict and rare but when occurring, even fatal. They are not dependent on 
pharmacologic response to the drug or the dose. The type of the drug-induced reaction depends 
on the associated drug and patient’s allele-carrying status. (Niemi, 2016; Pavlos et al., 2012; Yip 
et al., 2015) For example, if a patient carrying an HLA-allele HLA-B*58:01 initiates allopurinol, a 
risk for experiencing severe skin reactions Stevens-Johnson syndrome (SJS) or toxic epidermal 
necrolysis (TEN) is high. Allele carriers of HLA-B*15:02 are susceptible for developing SJS or TEN 
in case they are prescribed with carbamazepine, oxcarbazepine or phenytoin. However, 
carbamazepine is also associated with carrying an allele HLA-A*31:01 and a high risk for 
developing drug-induced hypersensitivity syndrome in addition to SJS and TEN. In addition to 
anticonvulsants and allopurinol, particular drugs of antiretrovirals, NSAIDs, sulpha antimicrobials 
and β-lactam antimicrobials can predispose the patient to drug-induced reactions along with HLA-
allele carrying status. (Pavlos et al., 2012) A common feature of the drug hypersensitivity 
syndromes is that they develop within 3 months of drug initiation and the recovery phase is long. 




supports targeted genetic testing. (Niemi, 2016; https://www.ncbi.nlm.nih.gov/gene/3105; 
https://www.ncbi.nlm.nih.gov/gene/3106; Pavlos et al., 2012; Yip et al., 2015)  
 
1.5. Pharmacogenetics-based guidelines 
 
To facilitate the implementation of PGx into daily clinical routines and to provide up-to-date 
information for clinicians, several evidence-based pharmacogenetic guidelines have been 
published. This study mainly utilizes the guidelines of Clinical Pharmacogenetics Implementation 
Consortium (CPIC) as a reference for the drugs in interest as for the prescribing recommendations. 
CPIC guidelines are peer-reviewed, evidence-based, updatable, detailed and freely available in the 
internet (https://cpicpgx.org/). A prescribing action proposed in the CPIC prescribing 
recommendations refers to a recommendation to choose alternative therapies or to adjust dose 
which highly likely results in more effective and safe treatment to the patient. CPIC lists drug-gene 
interaction pairs with respective guidelines and gives prescribing recommendations for clinicians to 
help drug selection and dose adjustment. Guidelines are categorized by the levels of evidence 
linking genotype to phenotype. Grading is based on literature evidence and consists of three 
categories; high, moderate and weak. Guidelines with the highest level of evidence are compiled 
based on consistent results from well-designed and well-conducted studies. Respectively, a 
guideline with weak level of evidence lacks adequate information due to small number of studies 
conducted or studies with inadequate design and evidence is insufficient when assessing the 
effects on health outcomes. To date, the CPIC has published 25 guidelines associated with wide 
range of drugs such as common analgesics, cardiovascular drugs and immunosuppressants, and 
the number of guidelines is constantly increasing and the existing guidelines are frequently 
updated. One guideline might refer to several drugs belonging into a same therapeutic group (e.g., 
CYP2D6, CYP2C19 and selective serotonin reuptake inhibitors), while one gene encoding for a 
particular CYP-enzyme might be associated to several drugs from different therapeutic group (e.g. 
CYP2C19 affecting both clopidogrel and voriconazole). (https://cpicpgx.org/; Lunenburg et al., 
2020) 
In addition to international and national expert consortia published PGx prescribing guidelines, the 
drug regulatory authorities in the United States and in Europe have regulatory guidelines 
concerning the conduction of genomic studies and use of genomic biomarkers in drug 
development. Genomic data is evaluated in the drug regulatory approval process if it is expected 







Abdullah-Koolmees et al., 2020, made a comparison of the guidelines published in English by the 
Dutch Pharmacogenetics Working Group (DPWG), the Clinical Pharmacogenetics Implementation 
Consortium (CPIC), the Canadian Pharmacogenomics Network for Drug Safety (CPNDS), and the 
French National Network (Réseau) of Pharmacogenetics (RNPGx). (Abdullah-Koolmees et al., 
2020) 
In their comparison Abdullah-Koolmees et al., found differences in e.g., methodologies to grade 
the scientific evidence, the amount of drug-gene interaction pairs evaluated, and differing 
recommendations for the drug dosing and patients to be genotyped. The guidelines are compiled 
similarly by multidisciplinary boards or committees, and all aim for compiling recommendations with 
high evidence-base and they constantly develop new recommendations and evaluate new data. 
The four committees have conducted harmonization projects and aim to use standardized terms 
as described in Caudle et al. (2017). Lately, one harmonization project resulted a consensus to 
downgrade the CYP2D6*10 allele activity score value. (Abdullah-Koolmees et al., 2020) 
In general, it has been recognised that the guidelines are of benefit for both clinicians and for 
patients as well as other stakeholders. Each PGx guideline project was based on different 
objectives, which have resulted unique guideline profiles and differing approaches but considering 
all guidelines simultaneously brings the most value. (Abdullah-Koolmees et al., 2020; Bank, PCD 
et al., 2017) 
 
1.6 Clinical implementation of pharmacogenetics 
Clinical implementation of pharmacogenetics into daily practise requires integration of genetic test 
results into electronic health records, and clinical decision support tools to provide patient-specific 
recommendations for clinicians. (Mukerjee et al., 2018) Various articles highlights the fact that the 
prescribing professionals are unfamiliar with PGx data and they are not educated to interpret the 
PGx test results. (Mukerjee et al., 2018; Bank, P. C. D. et al., 2019; Westergaard et al., 2020) 
Education is recognized to bridge the gap between the clinical reality and PGx prescribing 
guidelines, and which aspects should be considered regarding the gene test interpretation, 
genotype-to-phenotype translation, drug-drug interactions and comorbidities. (Just et al., 2019) In 




pharmacogenetics aims to personalised pharmacotherapy, improved adherence to drug therapy 
and increasing the patient’s quality of life. (Mukerjee et al., 2018; Westergaard et al., 2020; 
Lunenburg et al., 2020) 
Of the European countries, the Netherlands has implemented pharmacogenetics as a part of their 
drug database in electronical health care systems as a result an initiative by the Dutch 
Pharmacogenetics Working Group (DPWG). (Abdullah-Koolmees et al., 2020) The system gives 
an alert if it notices an interaction between the patient’s genotype and a drug prescribed or 
dispensed, and informs the clinician for the actions as well as the mechanisms behind the 
interaction. (Abdullah-Koolmees et al., 2020) 
Multiple prospective and large-scale PGx studies are ongoing, of which one of the most relevant is 
conducted by the Ubiquitous Pharmacogenomics consortium (U-PGx). Funded by the European 
Commission's Horizon2020 program, they investigate in a controlled clinical trial (PREPARE-study) 
how pre-emptive gene testing with a panel of clinically relevant PGx-markers would prevent 
adverse drug reactions. Furthermore, the impact on patient outcomes and cost-effectiveness will 
be discussed. The U-PGx study is conducted in seven European countries, and they aim to “make 
effective treatment optimization accessible to every European citizen”, according to the study web 
site. (van der Wouden, C. H. et al., 2017; http://upgx.eu/) 
In Finland, pharmacogenetics has been recognised as valuable tool in health care, although a wide 
implementation is still lacking. (Heliste et al., 2016) Costs related to increased number of 
pharmacogenetic tests, investments related to providing electronic decision support tools to 
clinicians and educating health care professionals to become familiar with pharmacogenetics were 
already 2016 seen as problems to slow the wide-scale clinical implementation. (Heliste et al., 2016) 
As a solution, Heliste et al., would include pharmacogenetics into national Current Care Guidelines 
(Käypä Hoito), including pharmacogenetics as a part of education programs for doctors and other 
health care professionals and that regulatory authorities would require pharmacogenetic data in 
summaries of product characteristics. They also proposed an interesting idea that reimbursements 
for medicine expenses would be approved after gene testing.  
Currently, the drug database by Duodecim includes a section GeneRx, to which all relevant 
information concerning pharmacogenetics has been included. The database provides basic 
information about the phenotypes associated with the drug, how they affect the drug dosing and 
metabolism, and which tests are recommended. The recommendations are primarily based on the 
CPIC prescribing guidelines. (https://www.terveysportti.fi/apps/generx/) The main problem is that 




prescribing situations. Practise for conducting pharmacogenetic tests is variable and is mainly 
based on single recommendations. The Current Care Guidelines on treatments related to 
psychiatric disorders recognises pharmacogenetic aspects important in successful 
pharmacotherapy (https://www.kaypahoito.fi/en) but the general common practise to utilize 
pharmacogenetics in prescribing is lacking, although significant attempts for genomic data 
utilization exists such as the National Genome Strategy 
(http://julkaisut.valtioneuvosto.fi/handle/10024/74514).  
A comprehensive analysis on the current implementation of PGx in the population level and its 
potential impact on improving health care and its economic consequences is still lacking. This might 
be the main reason for PGx not being routinely utilized in health care (Bank, P. C. D. et al., 2019; 
Lunenburg et al., 2020; Westergaard et al., 2020). Also, lack of widely adapted electronic decision 
support in clinics to utilize PGx information in daily prescribing and dispensing routines slows the 
clinical implementation (Bank, P. C. D. et al., 2019; Westergaard et al., 2020) 
 
1.7 Unique Finnish genetic heritage 
 
High variation occurs in worldwide distribution of genetic variation in drug metabolizing genes. 
Polymorphisms especially in genes coding for CYP-enzymes are common and extensively studied 
(Zhou et al., 2017). Low genetic drift between different ethnic groups and drift occurring mainly 
between individuals of the same population is the main factor of high interethnic genetic variation 
in worldwide scale. Demographic history and the germline variations present in individuals being 
settled in a specific area of the world create a genetic foundation for a population, which still has 
an impact. (Zhou et al., 2017; Sistonen et al., 2009) 
Finnish population represents a well-known genetic isolate, which express a unique genetic 
makeup due to several population bottlenecks and founder effects. (Jakkula et al., 2008; Sistonen 
et al., 2009; Varilo, 2016) First colonials arrived from south and south-east soon after the 
deglaciation of Fennoscandian Peninsula approximately 10,000 years ago. Later came settles from 
the Baltic region and west-Scandinavia, and the population was concentrated in the south-western 
and southern coastal parts of the country. The norther, eastern and middle parts of Finland were 
permanently inhabited relatively lately during the 16th and 17th centuries mainly by internal colonials. 
As a small number of settlers founded and inhabited each village, genetically and geographically 




Gene mutations occurred in the founder population also generated rare Finnish genetic diseases, 
which are more prevalent here than in any other parts of the world.  Altogether 36 mainly recessively 
heritable diseases caused by mutations in a single gene have been identified. (Varilo, 2016) 
Studies conducted with the late generations have revealed the geographic origin of the founder 
mutations. Moreover, genetic studies have revealed a difference in coronary heart disease mortality 
between the patients from eastern Finland and western Finland in addition to Y-chromosomal 
variation. (Jakkula et al., 2008; Sistonen et al., 2009) However, genetics linked to the Finnish 
heritable diseases are beyond the interest of this study. 
Due to the unique genetics, the distribution of particular variants of pharmacogenetically relevant 
genes differs from other European countries, and differences can be found even when comparing 
Finnish population with a population of East-Asian or African origin. (Tarkiainen et al., 2021) Due 
to genetic characteristics, results of the studies conducted with population other than Finnish origin 




Current knowledge on the topic pharmacogenetics is constantly increasing as the area is widely 
studied. Significant improvements in pharmacotherapy are recognized to be able to achieve by 
utilizing pharmacogenetic knowledge and patient-specific pharmacogenetic test results. Educating 
professionals to interpret the PGx test results and implement them into daily prescribing habits has 
been seen crucial. Up-to-date electronical health records and clinical decision support tools are 
recognised important factors as well as the patient engagement to obtain safe, effective, and 
personalized pharmacotherapy. Cost-effectiveness of pharmacogenetic testing requires additional 
studies to which this study or similar studies provide basic information to be further utilized. 
 
1.9 Aims of the study 
 
The purpose of this retrospective, register-based pharmacoepidemiologic study was to analyse the 
post-discharge purchases of drugs with an actionable pharmacogenetics-based prescribing 
guideline compiled and made available by the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) in a patient cohort consisting of Finnish hospital patients. The aim was to 
produce data to evaluate the potential impact of introduction of wide-scale (pre-emptive) 




The main hypothesis was that the drugs included into this study would be frequently used, which 
should have been seen in number of post-discharge drug purchases. Drug purchase frequency 
might be explained by patient group-specific factors and national treatment recommendations.  
Differences in post-discharge drug purchases between the patient groups included were studied.  
Additionally, the hypothesis was that generally the most relevant pharmacogenes, such as CYP-
genes equals with the most relevant pharmacogenes in this patient cohort. It was studied, which 
genes the drug purchases were associated to and which are pharmacogenetically the most relevant 
phenotypes in Finnish population by combining the Finnish phenotype frequencies with the drug 
incidence data and actionable prescribing recommendations.  
Based on these results, it was discussed whether it is possible to define a group of patients clearly 
benefiting from (pre-emptive) pharmacogenetic testing. Generally, it might be difficult to define 
exact criteria for the patient population and the current practise on pharmacogenetic testing is 
rather complex as there is need for reactive testing but clear benefits for both the patient and the 
society have been found with pre-emptive testing in intervention trials and attempts to implement 



















2.1 Patient cohort 
 
Total number of hospitalised patients meeting eligibility criteria was 1.42 million, half of them being 
men and 70% of them being discharged from surgical units. The median age of the patients was 
59 years. Demographic details of the patient cohort can be found in the Table 2.  
Table 2. Demographic details of the patient cohort 
 Number of patients Proportion of total n (%) 
Total 1 425 263 100 
- men 715 934 50.23 
- women 709 329 49.77 
Age – 18 – 24 yrs. 77 337 5.43 
- 25 – 44 yrs. 265 197 18.61 
- 45 – 64 yrs.  530 660 37.23 
- 65 – 80 yrs. 391 916 27.50 
- 80 – yrs.  160 153 11.24 
Patient distribution between 
units* 
  
- internal medicine 431 092 30.25 
- surgical  994 171 69.75 
*) This was the first qualifying hospital admission, which initiated the following as described in the Methods.  
 
2.2 Study drugs 
 
Altogether 33 unique drugs meeting eligibility criteria were identified from the CPIC prescribing 
recommendations.  The drugs were related to five different drug-metabolizing CYP-genes, four 
other pharmacokinetic genes, one gene encoding a pharmacological drug target and three HLA-
alleles associated with adverse drug reactions.  Drugs with their respective genes or gene alleles 
are listed in the Figure 3. Note that a particular drug can appear in multiple boxes when associated 





Figure 3. Drugs of interest in this study with each of their associated genes and HLA-alleles. 
Warfarin-associated CYP4F2 marked in parenthesis is not included in actual analyses but the 
CPIC recommendation for the gene is to be found in the table in the Appendix part of the thesis. 
 
2.3 Prevalence, incidence, CPIC recommendations and Finnish phenotype 
frequencies 
 
Drug purchases 180 days before the initiative hospital admission were noted in prevalence rate 
calculations to describe the active drug use at the moment of hospital admission. The prevalence 
rates varied from <0.1% to 14.6% proportionated in the total population. Drugs such as 
atomoxetine, fluvoxamine, mercaptopurine and trimipramine had the lowest prevalence rates 
(<0.1%). Drugs such as codeine, ibuprofen, pantoprazole, simvastatin and warfarin had the highest 
prevalence rates, varying from 6.6% for both codeine and warfarin to 14.6% for simvastatin. No 
drug purchases before the initiative hospital admission were detected for thioguanine, and 




Drug purchases during 2-year follow-up were noted in incidence rate calculations. The incidence 
rate varied from <0.1% to 25.0%, being lowest for drugs such as atomoxetine, fluvoxamine, 
mercaptopurine and tacrolimus (<0.1%) and highest for codeine (19.4%), ibuprofen (25.0%), 
pantoprazole (12.5%), simvastatin (5.9%) and warfarin (5.4%). No new drug initiations were 
detected for piroxicam.  
Finnish phenotype frequencies retrieved from literature references or from the SISU-database 
varied for each gene or HLA-allele. Regarding the phenotypes categorized as actionable, the 
frequencies of actionable phenotypes in Finnish population varied from 0.27% for HLA-B*58:01 
associated with allopurinol to 63% for VKORC1 associated with warfarin. Phenotype frequency of 
HLA-B*15:02 was not found for Finnish population as the allele is extremely rare in Finland. Drug 
purchases over 1% of the total study population, which were estimated to be associated with an 
actionable phenotype were of clopidogrel, codeine, ibuprofen, meloxicam, simvastatin and warfarin 
in 2-year follow-up.  
Prevalence and incidence rates of drug purchases, a symbol indicating the content of CPIC 
recommendation, actionability of the recommendations, the Finnish phenotype frequencies 
reported in the literature and a calculated prediction of new drug initiations for each phenotype were 
assembled into Table 3 below. The full CPIC recommendations were truncated in the table but the 
main details of the recommendations can be found in the Appendices of this thesis and the full 
recommendations in the original CPIC publications (https://cpicpgx.org/ ). 
It is to be noted that a single drug can appear more than one time in the table if it is associated with 
multiple genes or alleles. Both the prevalence and the incidence rates, as well as the predicted 
number of new drug initiations for each phenotype were proportionated to the total number of study 











Table 3. Prevalence and incidence of the drug purchases for each gene or allele and the predicted 
























drug users  










● 0,27 % 64 
(<0,1%) 
(Ref. 5)    HLA-B*58:01 
negative/ 
non-carrier 
□ 99,73 % 23499 
(1,6 %) 






● (or ▲) 7,00 % 1124 
(<0,1 %) 
(Ref. 3)    NM (AS 
>1.25 - 
<2.25) 
□ 62,00 % 9953 
(0,7 %) 
    IM (AS >0 - 
<1.25) 
▼ 29,00 % 4656 
(0,3 %) 
    PM (AS 0) ● (or ▼) 3,00 % 482 
(<0,1 %) 




UM and RM ● (or ▲) 26,00 % 4174 
(0,3 %) 
(Ref. 3)    NM □ 33,00 % 5298 
(0,4 %) 
    IM □ 36,00 % 5779 
(0,4 %) 
    PM ● (or ▼) 5,00 % 803 
(<0,1%) 






□ 7,00 % 2 
(<0,1%) 
(Ref. 3)    NM (AS 
>1.25 - 
<2.25) 
□ 62,00 % 17 
(<0,1%) 





(<0,1%)     IM (AS 0.25-
0.75) 
» 
    PM (AS 0) » 3,00 % 1 
(<0,1%) 






96,30 % 5297 
(0.4%) 
(Ref. 2)    IM or 
possible IM 
▼ 3,60 % 198 
(<0,1%) 




























drug users  
(% of total n)  




NM □ 93,10 % 5121 
(0,4 %) 
(Ref. 1)    IM or 
possible IM 
▼ 6,80 % 374 
(<0,1%) 
    PM ▼ 0,10 % 6 
(<0,1%) 




NM (AS 2) □ 92,20 % 8544 
(0,6 %) 






(<0,1%)     IM (AS 1) ▼ 






















(Ref. 3)    HLA-B*15:02 
negative/ 
non-carrier 










● 3,50 % 147 
(<0,1%) 
(Ref. 5)    HLA-A*31:01 
negative/ 
non-carrier 
□ 96,50 % 4059 
(0,30 %) 




NM (AS 2) □ 67,00 % 8783 
(0,6 %) 






(0,3 %)     IM (AS 1.0) ▼ 
    PM (AS 0 - 
0.5) 
▼or ● 3,00 % 393 
(<0,1%) 




UM ● 26,00 % 6964 
(0,5 %) 
(Ref. 3)    EM □ 33,00 % 8839 
(0,6 %) 
    IM □ 36,00 % 9643 
(0,7 %) 




























drug users  
(% of total n)  






● (or ▲) 7,00 % 24 
(<0,1%) 
(Ref. 3)    NM (AS 
>1.25 - 
<2.25) 
□ 62,00 % 211 
(<0,1%) 
    IM (AS >0 - 
<1.25) 
▼ 29,00 % 99 
(<0,1%) 
    PM (AS 0) ● (or ▼) 3,00 % 10 
(<0,1%) 




UM and RM ● (or ▲) 26,00 % 88 
(<0,1%) 
(Ref. 3)    NM □ 33,00 % 112 
(<0,1%) 
    IM □ 36,00 % 122 
(<0,1%) 
    PM ● (or ▼) 5,00 % 17 
(<0,1%) 




UM □ 26,00 % 15259 
(1,1 %) 
(Ref. 3)    EM □ 33,00 % 19368 
(1,4 %) 
    IM ● 36,00 % 21128 
(1,5 %) 
    PM ● 5,00 % 2935 
(0,2 %) 




UM (AS > 
2.25) 
● 7,00 % 19319 
(1,4 %) 
(Ref. 3)    NM (AS 
>1.25 - 
<2.25) 
□ 62,00 % 171107 
(12,0 %) 
    IM (AS >0 - 
<1.25) 




    PM (AS 0) ● 3,00 % 8279 
(0,6 %) 






● (or ▲) 7,00 % 173 
(<0,1%) 
(Ref. 3)    NM (AS 
>1.25 - 
<2.25) 
□ 62,00 % 1531 
(0,1 %) 
    IM (AS >0 - 
<1.25) 
▼ 29,00 % 716 
(<0,1%) 




























drug users  
(% of total n)  




UM and RM ● (or ▲) 26,00 % 642 
(<0,1%) 
(Ref. 3)    NM □ 33,00 % 815 
(<0,1%) 
    IM □ 36,00 % 889 
(<0,1%) 
    PM ● (or ▼) 5,00 % 124 
(<0,1%) 




UM ● 26,00 % 8085 
(0,6 %) 
(Ref. 3)    EM □ 33,00 % 10261 
(0,7 %) 
    IM □ 36,00 % 11194 
(0,8 %) 
    PM ▼ or ● 5,00 % 1555 
(0,1 %) 






▬ 7,00 % 20 
(<0,1%) 
(Ref. 3)    NM (AS 
>1.25 - 
<2.25) 
□ 62,00 % 177 
(<0,1%) 
    IM (AS >0 - 
<1.25) 
□ 29,00 % 83 
(<0,1%) 
    PM (AS 0) ▼ or ● 3,00 % 9 
(<0,1%) 





NM (AS 2) □ 67,00 % 239140 
(16,8 %) 




(7,5 %)     IM (AS 1.0) ▼ 
    PM (AS 0 - 
0.5) 
▼or ● 3,00 % 10708 
(0,8 %) 




UM ▲ 4,00 % 2357 
(0,2 %) 
(Ref. 3)    RM □ 22,00 % 12963 
(0,9 %) 
    NM □ 33,00 % 19444 
(1,4 %) 
    IM and likely 
IM 
□ 36,00 % 21212 
(1,5 %) 
    PM and 
likely poor 
□ 5,00 % 2946 
(0,2 %) 




NM (AS 2) □ 67,00 % 29266 
(2,1 %) 







    IM (AS 1.0) ▼or ● 
    PM (AS 0 - 
0.5) 




























drug users  
(% of total n)  




NM □ 96,30 % 873 
(<0,1%) 
(Ref. 2)    IM or 
possible IM 
▼ 3,60 % 33 
(<0,1%) 
    PM ▼ 0,10 % 1 
(<0,1%) 




NM □ 93,10 % 844 
(<0,1 %) 
(Ref. 1)    IM or 
possible IM 
▼ 6,80 % 62 
(<0,1 %) 
    PM ▼ 0,10 % 1 
(<0,1 %) 






● (or ▲) 7,00 % 108 
(<0,1%) 
(Ref. 3)    NM (AS 
>1.25 - 
<2.25) 
□ 62,00 % 958 
(<0,1%) 
    IM (AS >0 - 
<1.25) 
▼ 29,00 % 448 
(<0,1%) 
    PM (AS 0) ● (or ▼) 3,00 % 46 
(<0,1%) 




UM ▲ 4,00 % 2365 
(0,2 %) 
(Ref. 3)    RM □ 22,00 % 13006 
(0,9 %) 
    NM □ 33,00 % 19509 
(1,4 %) 
    IM and likely 
IM 
□ 36,00 % 21282 
(1,5 %) 
    PM and 
likely poor 











● N/A  
(Ref. 3)    HLA-B*15:02 
negative/ 
non-carrier 
□ N/A  
 




UM ▲ 4,00 % 7128 
(0,5 %) 
(Ref. 3)    RM □ 22,00 % 39203 
(2,8 %) 
    NM □ 33,00 % 58804 
(4,1 %) 
    IM and likely 
IM 
□ 36,00 % 64150 
(4,5 %) 
    PM and 
likely poor 




























drug users  
(% of total n)  






● 7,00 % 162 
(<0,1%) 
(Ref. 3)    NM (AS 
>1.25 - 
<2.25) 
□ 62,00 % 1436 
(0,1%) 
    IM (AS >0 - 
<1.25) 
□ 29,00 % 672 
(<0,1%) 











● N/A   
(Ref. 3)    HLA-B*15:02 
negative/ 
non-carrier 
□ N/A  




NM, AS 2 □ 67,00 % 886 
(<0,1%) 









    IM, AS 1.0 ▼ 
    PM, AS 0.5 ▼ 
    PM, AS 0 ▼ 3,00 % 40 
(<0,1%) 






NM □ 67,00% N/A 






    IM, AS 1.0 ● 
    PM ● 3,00% N/A 




UM □ 26,00 % 2065 
(0,1 %) 
(Ref. 3)    EM □ 33,00 % 2622 
(0,2 %) 
    IM □ 36,00 % 2860 
(0,2 %) 
    PM ▼ or ● 5,00 % 397 
(<0,1%) 







□ 60,00 % 50179 
(3,5 %) 
(Ref. 3)    intermediate 
function 
▼ or ● 35,00 % 29271 
(2,1 %) 




























drug users  
(% of total n)  







▲ 0,50 % 3 
(<0,1%) 
(Ref. 3)    IM (CYP3A5 
expresser) 
▲ 13,00 % 77 
(<0,1%) 
    PM (CYP3A5 
nonexpresser) □ 
86,00 % 507 
(<0,1%) 




UM (AS > 
2.25) 
□ 7,00 % 573 
(<0,1%) 
(Ref. 3)    NM (AS 
>1.25 - 
<2.25) 
□ 62,00 % 5072 
(0,4 %) 
    IM (AS 
>0,25-<1.25) 
● (or ▲) 29,00 % 2372 
(0,2 %) 
    PM (AS 0) ● (or ▲) 3,00 % 245 
(<0,1%) 




NM □ 96,30 % 2 
(<0,1%) 
(Ref. 2)    IM or 
possible IM 
▼ 3,60 % 0 
(<0,1%) 
    PM ▼ 0,10 % 0 
(<0,1%) 




NM □ 93,10 % 2 
(<0,1%) 
(Ref. 1)    IM or 
possible IM 
▼ 6,80 % 0 
(<0,1%) 
    PM ▼ 0,10 % 0 
(<0,1%) 






● (or ▲) 7,00 % 60 
(<0,1%) 
(Ref. 3)    NM (AS 
>1.25 - 
<2.25) 
□ 62,00 % 536 
(<0,1%) 
    IM (AS >0 - 
<1.25) 
▼ 29,00 % 251 
(<0,1%) 
    PM (AS 0) ● (or ▼) 3,00 % 26 
(<0,1%) 




UM and RM ● (or ▲) 26,00 % 225 
(<0,1%) 
(Ref. 3)    NM □ 33,00 % 285 
(<0,1%) 
    IM □ 36,00 % 311 
(<0,1%) 





AS = activity score, N/A = not applicable, symbols: dose increase ▲, dose decrease ▼compared to normal dosing 
strategy, alternative drug recommended/drug contraindicated ●, normal starting dose/no specific actions needed □, 
no recommendation due to lack of evidence ▬, slower dose increase/titration to therapeutic level », recommendation 
in parenthesis as a secondary option and requiring specific monitoring. Red indicates actionable and green non-
actionable recommendations. Phenotype frequency references: 1) Zhou et al, 2020; 2) Häkkinen et al., preprint 2020; 

































drug users  
(% of total n)  




UM ● 4,00 % 11 
(<0,1%) 
(Ref. 3)    RM ● 22,00 % 62 
(<0,1%) 
    NM □ 33,00 % 93 
(<0,1%) 
    IM □ 36,00 % 102 
(<0,1%) 
    PM ● or ▼ 5,00 % 14 
(<0,1%) 




NM (AS 2) 
Non-African 
*1 
□ 67,00 % 51747 
(3,6 %) 
(Ref. 3)    IM (AS 1 - 
1.5) Non-
African *2 
▼ 30,00 % 23170 
(1,6 %) 
    PM (AS 0 - 
0.5) Non-
African *3 
▼ 3,00 % 2317 
(0,2 %) 







□ 37,00 % 28577 
(2,0 %) 
(Ref. 3)    IM, Non-
African 
1639G/A 
▼ 48,00 % 37072 
(2,6 %) 
    PM, Non-
African 
1639A/A 





2.4 New drug initiations for associated genes and HLA-alleles of interest 
 
Following graphical visualization (Figure 4) shows the post-discharge drug purchases associated 
to genes and HLA-alleles of interest. The whole study period of 2008-2016 was considered. When 
associated with several genes, the drug purchase was considered in analyses of every associated 
gene. Note, that CYP4F2 associated with warfarin is not included here but its proportion is the 




Figure 4. Post-discharge drug purchases associated to genes and HLA-alleles of interest during 
the whole study period 2008-2016 (730 days). X-axis shows the days since hospitalisation and y-
axis the proportion of patients of total number of patients, whose drug purchase were associated 

































CYP2C9 CYP2C19 CYP2D6 CYP3A5
SLCO1B1 NUDT15 HLA-A*31:01 HLA-B*58:01





2.5 Drugs purchased in 2-year follow-up 
 
Of the drugs included into this study, ten of the most frequently purchased drugs in 2-year follow-
up included common analgesics, proton pump inhibitors, a cholesterol-lowering drug, an 




Figure 5. New drug initiations in 2-year follow-up from most used to less used (x-axis) 
proportionated in total patients (y-axis). A digit above each of the bars represents the proportion of 













































































































































































































































































































































2.6 Cumulative account of post-discharge drug purchases 
 
Results showed that in 1-year follow up, 51% of patients (n=722194 patients) purchased at least 
one of the drugs of the interest (Figure 6). The amount of patients increased in 2-year follow-up, 
when 60% of patients (n=860449 patients) initiated at least one of the drugs of interest. Patients 




Figure 6. Number of drugs purchased per patient in 1-year (blue bars) and 2-year follow up (orange 
















































































































In this study, the number of different genes associated to overall number of post-discharge drug 
purchases for a patient were calculated. Results showed that 22% of the study population (311318 
patients) purchased drugs associated with ≥ 2 different genes (Figure 7). Drug purchases 
associated with ≥4 genes were rare but occurred even up to 7 associated genes for a patient.  
 
 
Figure 7. Drug purchases associated to the number of genes in 1-year and 2-year follow-up 
 
 
2.7 Cox regression analysis  
 
Table 4 shows the Cox regression analysis model results with p-values, hazard ratios and 
confidence interval with 95% range. In case the hazard ratio (HR) is above 1, the surgical unit 
patients have a higher risk for drug purchase, while HR being under 1, the risk for a drug purchase 
is higher in patients discharged from the internal medicine unit. The Cox regression model showed 
that patients being discharged from the surgical unit had an overall greater probability to purchase 



































































































ratio 1.23, 95% confidence interval 1.22-1.23). Analysing single genes separately, the results 
indicate that surgical unit patients had a greater probability to purchase a drug metabolized by 
CYP2C9 (HR 1.66, 95% CI 1.65-1.67), CYP2D6 (HR 1.54, 95% CI 1.53-1.55) and DPYD (HR 2.32, 
95% CI 2.21-2.43).  
 
Table 4. Cox regression univariate analysis on proportional risk for drug purchase, patients 
discharged from the internal medicine unit vs. patients discharged from the surgical unit 
Gene HR* 95% CI** low 95% CI high P-value 
any/all combined 1.23 1.22 1.23 <.0001 
CYP2C19 0.64 0.63 0.64 <.0001 
CYP2C9 1.66 1.65 1.67 <.0001 
CYP2D6 1.54 1.53 1.55 <.0001 
CYP3A5 0.25 0.22 0.28 <.0001 
DPYD 2.32 2.21 2.43 <.0001 
NUDT15 0.32 0.31 0.34 <.0001 
TPMT 0.32 0.31 0.34 <.0001 
SLCO1B1 0.41 0.41 0.42 <.0001 
VKORC1 0.28 0.28 0.28 <.0001 
HLA-A*31:01 0.88 0.84 0.92 <.0001 
HLA-B*15:02 0.83 0.80 0.86 <.0001 
HLA-B*58:01 0.46 0.45 0.46 <.0001 















The primary aim of this study was to produce data to evaluate the potential impact of introduction 
of wide-scale (pre-emptive) pharmacogenetic testing in Finnish health care. The main hypothesis 
was that the drugs included into this study would be frequently used, which should have been seen 
in number of post-discharge drug purchases. It was studied to which genes the drug purchases of 
this study cohort were associated with and the results were compared to the most relevant 
pharmacogenes in general. Possible differences in post-discharge drug purchases between the 
patient groups included were shortly studied. 
 
3.1 Drug use of the patient cohort 
 
The drugs of interest were identified from the CPIC recommendations represents commonly used 
drugs from several pharmacological groups; analgesics, anticonvulsants, antidepressants, 
immunosuppressants, antineoplastics and drugs for cardiovascular and gastrointestinal diseases 
in addition to singular drugs from selective norepinephrine reuptake inhibitors, antigout and 
antimycotic drug groups (Figure 3). Of these ten of the most frequently initiated drugs were 
ibuprofen, codeine, pantoprazole, simvastatin, warfarin, omeprazole, lansoprazole, clopidogrel, 
meloxicam and escitalopram (Figure 5). Drugs with a lower incidence rate represent drugs, which 
were expected to be less used, such as tricyclic antidepressants (e.g., trimipramine and 
clomipramine), immunosuppressants (e.g., mercaptopurine and thioguanine) and a 
selective norepinephrine reuptake inhibitor atomoxetine. Marketing authorisation of oral piroxicam 
was terminated during the study years, and no new drug initiations of piroxicam was seen. This 
verifies our hypothesis that the drugs of interest are widely used and represent various drug 
categories. The results were expected and any surprisingly high or low incidence rates of the drugs 
were not seen.  
Most of the drugs (25 out of 33) are related to the CYP450-system and therefore genetic 
polymorphism of genes coding CYP-enzymes affects their dosing (Figure 3). In addition to CYP-
genes, four other pharmacokinetic genes, one gene encoding a pharmacological drug target and 
three HLA-alleles altering to susceptibility to adverse effects were included.  
Most frequently the drug purchases were associated with genes CYP2C9, CYP2D6 and CYP2C19 
(Figure 4). Low number of drug initiations were associated with genes CYP3A5, NUDT15, TPMT, 




rates related to the genes can be explained by the number of drugs associated to each of the genes 
and differences in incidence rates of these drugs.  
Of the most used drugs a clear need for post-operative pain management explains the high 
incidence rate of ibuprofen, codeine, meloxicam and celecoxib. High incidence rate of simvastatin, 
clopidogrel and warfarin might be explained by the diagnoses of the patients discharged from the 
internal medicine unit. Both are indicated to treat conditions related to cardiovascular diseases, 
which are typical diagnoses of the patients in the internal medicine unit. If more recent drug 
purchase data would have been available, the incidence rates for clopidogrel and warfarin would 
highly like have been lower as the current common practise recommends prescribing of novel drugs 
such as apixaban or dabigatran instead of clopidogrel or warfarin. 
High incidence rates for each of the proton pump inhibitors involved (pantoprazole, lansoprazole 
and omeprazole) might be explained by the indications strongly linked to the conditions treated in 
internal medicine unit. On the other hand, a proton pump inhibitor can be used in a combination 
with a NSAID-drug to prevent NSAID-induced ulcers. NSAID-drugs being frequently used in this 
population might lead to higher incidence rates for proton pump inhibitors used for this indication.  
Factors explaining low incidence rates for drugs such as tricyclic antidepressants, 
immunosuppressants, voriconazole and anticonvulsants might be the patients-specific factors such 
as the diagnoses of the patients and common practises to prescribe drugs. For example, the use 
of tricyclic antidepressants is relatively low as novel antidepressants have accessed the markets. 
Low number of drug purchases of atomoxetine might be explained by the fact that the drug is not 
the primary alternative in the treatment of adulthood ADHD and the number of patients having an 
adulthood ADHD is relatively low. Patient cohort of this study consists only adult patients, which 
highly likely explains the low rate of new drug initiations.  
Prevalence was calculated for each of the study drugs to describe the active drug use at the 
moment of hospital admission in 180 days before the initiative hospital admission (Table 3). 
Typically, the prevalence rate correlates with the incidence rate. If the prevalence of a drug was 
low, the incidence was low as well, although in general, the incidence rate was slightly higher than 
the prevalence rate for a drug. The most significant differences between the prevalence and 
incidence rates are in codeine (prevalence 6.6%, incidence 19.4%) and ibuprofen (prevalence 
14.1%, incidence 25.0%) which clearly indicates the need of post-operative pain management after 
discharge from surgical units. Moreover, prevalence and incidence differ from each other also in 
pantoprazole and clopidogrel (pantoprazole prevalence 7.1%, incidence 12.5%, clopidogrel 0.9% 




simvastatin and warfarin, the incidence rate was lower than prevalence rate (simvastatin 
prevalence 14.6%, incidence 5.9%, warfarin 6.6.% and 5.4%, respectively), which are commonly 
initiated drugs in both inpatient care and outpatient care.  
Drugs identified for this study were similar with other pharmacoepidemiologic register studies with 
rather similar or otherwise comparable study setting (Lunenburg et al., 2020; Alshabeeb et al., 
2019; McInnes et al., 2020; Westergaard et al., 2020) Differences are explained by the reference 
prescribing guidelines used, availability of the drugs, and which drugs the researches have seen 
relevant to include in their study. In addition, McInnes et al., were able to utilize biobank data in 
their study. In these studies, it was estimated that approximately 23-25% of the study population 
had an actionable phenotype. This was not possible to simply calculate in this study as we did not 
have the individual level drug purchases available and drug purchases were registered in each of 
their associated genes or alleles leading to purchase duplications.  
A cumulative account of the post-discharge drug purchases showed that in 2-year follow up 60% 
of the total population initiated at least one of the study drugs (Figure 6). Should the patient have 
an actionable phenotype associated to the drug purchase, the drug initiation would have been 
pharmacogenetically actionable. It would have been interesting to know how many of these patients 
had an actionable phenotype requiring either dose increase or decrease or an alternative drug but 
unfortunately such data was not available.  
The post-discharge drug purchases associated with the number of different genes for a patient 
showed that purchases of 56% of the population was associated with at least one of the genes of 
interest (Figure 7). In this analysis, each drug purchase was registered in each of its associated 
genes.  
Both cumulative analyses show that the drugs were frequently used by the majority of the patients. 
A great number of patients purchased several drugs of interest during the follow-up and the drug 
purchases were associated in multiple different genes in significant number of the patients. This 
indicates that majority of the patients were polypharmacy patients. In addition, it is to be noted that 
this does not represent all the drugs in use for a patient and the number of drugs in use is higher 
in reality. This leads to more complicated situation as there is a high likelihood to drug-gene 






3.2 Cox regression analysis results 
 
One of the aims of this study was to examine the differences in post-discharge drug purchases 
between patients discharged from surgical unit with patients discharged from internal medicine unit 
in Cox proportional-hazards model adjusted for type of the hospital unit (Table 4). Based on the 
results, patients being discharged from the surgical unit had a greater probability to initiate new 
drug therapy associated with genes CYP2C9, CYP2D6 and DPYD, which might lead to the overall 
greater probability to drug purchases than patients discharged from the internal medicine unit. 
Frequently purchased analgesics ibuprofen and codeine associated with genes CYP2C9 and 
CYP2D6 definitely explain the majority of the results. Also, warfarin and meloxicam, both in ten 
most frequently purchased drugs, associated with CYP2C9 have an impact on the probability. The 
use of analgesics is highlighted in this study population, which can be thought to give a reason for 
pre-emptive PGx testing to achieve sufficient post-surgery pain management. For warfarin, specific 
dosing algorithms are already in use, which include both clinical and genetic factors to determine 
individual drug dose.  
Antineoplastic capecitabine is the only drug associated with the gene DPYD in this study. A factor 
explaining the greater probability to initiate capecitabine after discharge from surgical unit might be 
that it is used for the adjuvant treatment of patients following surgery of stage III colon cancer 
according to the summary of product characteristics of Xeloda (one of the brand names of 
capecitabine) (https://www.ema.europa.eu/en/documents/product-information/xeloda-epar-
product-information_en.pdf). In April 2020 the European Medicines Agency (EMA) published a 
recommendation to test patients for the lack of enzyme dihydropyrimidine dehydrogenase (DPD) 
encoded by gene DPYD before initiating fluorouracil or fluorouracil-related drug treatment. Patients 
suffering from complete lack of DPD cannot utilize pharmacotherapy such as capecitabine, which 
is an orally administered precursor of 5-fluorouracil. In partial DPD deficiency, diminished 
capecitabine doses should be used. Patients having a complete or partial DPD deficiency are at 
increased risk for fatal or life-threatening fluoropyrimidine-related toxicity, such as stomatitis, 
diarrhoea, mucosal inflammation, neutropenia and neurotoxicity 
(https://www.ema.europa.eu/en/documents/product-information/xeloda-epar-product-
information_en.pdf) Phenotype frequency for partial DPD deficiency in Finnish population is 7.7% 
and 0.14% for complete lack of the DPD enzyme. Conclusively, pre-emptive testing of DPYD 
variants is highly recommended but as a basis of general recommendation, not specifically based 




Internal medicine unit patients had a higher probability to a drug purchase associated with 
CYP2C19, CYP3A5, NUDT15, TPMT, SLCO1B1, VKORC1 and each of the HLA-alleles. Patient-
specific factors such as the diagnoses might have an impact on the drug purchase. For example, 
a higher probability to drug purchase associated with SLCO1B1 could be explained by its 
associated drug simvastatin, which is more linked to the diagnoses of the internal medicine unit 
patients than with the surgery unit patients.  
However, based on these results, it is challenging to recommend any specific PGx tests to a certain 
patient group. This would have required more elaborate analysis focusing specifically on the 
background factors and comorbidities, which falls beyond the scope and time resources of this 
study. Generally, it has been discussed whether it is possible to define any clear and simple criteria 
for a patient group clearly benefiting from pre-emptive pharmacogenetic testing. Most of all, it 
should be considered that the type of gene assay chosen is sensitive enough to detect all relevant 
alleles in the population to be genotyped, validated laboratory technology is used to provide reliable 
results, the test results should be stored to a database from which they are easily available and 
that the results are interpreted by a professional with adequate knowledge on pharmacogenetics, 
which requires education of health care professionals most preferably already in their degree 
programmes. As direct costs of the testing might not be the main problem as the price for the testing 
has decreased due to modern sequencing technology, it should be concentrated that the testing is 
cost-effective. This study and similar studies are needed to provide valuable information of the drug 
initiations and to which genes they are associated with to be further utilized in cost-effectiveness 
studies.  
 
3.3 Finnish phenotype frequencies 
 
Phenotype frequencies of each metabolizing phenotypes were estimated using previously 
published studies and the SISu-database for single nucleotide variants (Table 3). Article references 
approved should have been relatively lately published to ensure up-to-date interpretation of allele 
functions as the area is constantly updating and developing. Furthermore, it was preferred that the 
study population for genotyping should not have been skewed in any way, for example represent 
a specific patient group in which some alleles might be linked to the disease to ensure that no 
specific allele is unusually frequent. If possible, studies conducted with a great number of 
participants for genotyping were preferred to provide statistical power. In general, adequate 
phenotype frequency references were possible to find. For the gene NUDT15, an article reference 




studied individuals with psychotic disorders, which refers to a skewed study population and leads 
to an assumption that results cannot be applied to whole population level. However, NUDT15 
variants are usually interpreted together with TPMT variants for the associated drugs azathioprine, 
mercaptopurine and thioguanine, which decreases the impact of either of the genes alone. A 
general problem in finding relevant previously published studies of phenotype frequencies was that 
in multi-ethnic studies persons of Finnish origin had been excluded due to unique genetic heritage. 
Any phenotype frequency for HLA-B*15:02 was not found as it is considered very rare in Finland 
but the allele is common in East-Asian and African populations.  
 
3.4 Pharmacogenetic prescribing recommendations 
 
Due to limited time resources of this thesis project, the prescribing recommendations of only the 
CPIC were possible to include. CPIC recommendations were chosen due to easy-access via 
internet, up-to-date information, comprehensively evaluated drug-gene pairs and easy application 
with the drugs marketed in Finland. All relevant updates were aimed to include, although it is to be 
noticed that the area is constantly updating and developing. By choosing different guidelines or 
conducting this study earlier without newest guidelines on proton pump inhibitors or non-steroidal 
anti-inflammatory drugs or the update to the guideline on opioids, the results would have been 
totally different.  
As mentioned earlier, interpretation of the results should be made by a health care professional 
with knowledge on pharmacogenetics. Although the testing results remain unchangeable, the 
interpretation might change due to novel information about the allele functions. The most relevant 
update in recent years have occurred with allele CYP2D6*10 function status. Recently, CPIC and 
DPWG reached a consensus to downgrade the allele activity score from 0.5 to 0.25. In addition, 
normal metabolizer phenotype with an activity score 1 is currently translated as intermediate 
metabolizer in consistency with the novel information of the allele function. (Caudle et al., 2020) 
The allele activity score downgrading was observed in the latest update to the CPIC guideline on 
opioids. In this study, this update was noticed also in the context of other phenotypes associated 







3.5 Pharmacogenetic testing 
 
Currently, the pharmacogenetic testing is based on either reactive (“as needed”) or pre-emptive 
testing. Specific, well-known single nucleotide variants are tried to detect in gene assays. In 
choosing a suitable assay depends on the target population to be tested. The assay chosen should 
be specific and sensitive enough to detect the variants frequent in the target population. Tests to 
detect variants of a specific gene or a panel consisting of multiple genes are used. As mentioned, 
the interpretation of pharmacogenetic testing is rather complex and should be conducted with 
relevant knowledge on pharmacogenetics. Although testing results has been widely underlined as 
“life-long” and permanent, the possible changes in the interpretation should be noticed. The test 
results obtained in a specific time point might need to be re-evaluated after discovery of novel 
alleles or novel information on allele functions of the earlier identified alleles. The area of 
pharmacogenetics is constantly changing and evolving, which has been seen as well during this 
study.  
 
3.6 Drug use in Finland 
 
In Finland, patients can utilize world-wide rather exceptional reimbursements for medical expenses 
provided by the Social Insurance Institution of Finland (KELA). This leads to the situation that health 
care costs for drug purchases are reasonable and the drug is not selected by the patients’ ability 
to pay. The reimbursements are categorised in three categories based on the indication and how 
critical the drug is for the patient. In the USA for example, the situation is different and inequal for 
the patients. Medical expenses are frequently covered by insurances, which are not similar for the 
citizens. This can have an effect in both which drugs doctor selects for the patients and which drugs 
are dispensed from the pharmacies. 
The most frequently initiated drug in this study was ibuprofen. This might be explained by the 
current national practise to initiate ibuprofen after an operation, which might be seen in patients 
discharged from the surgical unit. Another reason might be the exceptional status of ibuprofen in 
Finland due to strong national brand Burana from the pharmaceutical company Orion.  
Moreover, national Current Care Guidelines (Käypä Hoito suositukset) guide doctors in prescribing, 
which have a strong impact in drug initiations. The Current Care Guidelines might differ from 
recommendations in other countries, although they are compiled based on national guidelines with 





3.7 Patients other than Finnish origin 
 
This study was conducted with a patient cohort consisting of Finnish patients. It was assumed that 
the majority of patients represent people of Finnish origin, and Finnish citizens other ethnic origin 
represent a minority. As the exact ethnical origin of the patients was not known, nor the genotype 
data was available, phenotype frequencies reported in previous studies for individuals of Finnish 
origin were utilized in assessing the impact of the results in Finland. 
As mentioned earlier, the unique Finnish gene heritage compared to other north European 
countries was a strong argument for the study execution, as a clear need is recognized for national 
pharmacogenetic studies, which consider various ethnical aspects of the study population. 
However, multiethnicity is common in daily patient care situations. Clinicians should be aware of 
the aspects in different ethnical groups, which are relevant to consider in pharmacotherapy 
planning and execution and in patient care in general. Mandated in law, all people without regarding 
their ethnical background have an equal right to health care.  
In pharmacogenetics, differences in phenotype frequency distribution between different ethnical 
groups but also among them are significant. The aim should be to identify the ethnical groups 
having a high possibility to carry a pharmacogenetically relevant actionable phenotype or alleles 
linked to that. For example, carrying an HLA-allele HLA-B*15:02 is rare among individuals of 
Finnish origin but the allele is common in East-Asian and African populations. In case a patient of 
East-Asian origin needs a drug associated with HLA-B*15:02, a pre-emptive pharmacogenetic 
testing is highly recommended in order to avoid possible severe adverse drug reactions. Initiation 
of HLA-B*15:02 associated drugs can lead to drug hypersensitivity reactions such as Steven’s 
Johnson syndrome.  
 
3.8 Study strengths 
 
The most significant strength of this study is the high number of patients involved in the patient 
cohort (n=1.42 million), which represents about 26% of the whole Finnish population (5.54 million).  
Most of the patients belong to a group of 45-64-year-old patients (37%), followed by 65-80-year-
old patients (28%). Young adults in 18-24 years of age represent the smallest age group (5%), 




59 years, and the patient cohort was a comprehensive sample of adult population in Finland (Table 
2). 
In this study the register data was based on three registers of hospital admissions, drug purchases 
and mortality data. Different Finnish population registers provide with an exceptionally wide and 
detailed information platform to be utilized in register-based studies. Additionally, utilizing Finnish 
registers leads to the conclusion that the results of this study are directly applicable to Finnish 
population as such. Moreover, it is utmost important to utilize Finnish phenotype frequencies 
because significant differences have been found in phenotype frequencies of other ethnicities, 
which would have led to different results. 
This study utilized prescribing recommendations compiled by CPIC, which were carefully reviewed 
manually to identify eligible drugs for the study. All eligibility criteria for both the drugs and for the 
patient cohort were detailed carefully to meet high level standards for pharmacoepidemiologic 
study. In prescribing recommendation actionability determination, thoughts were put on reasonable 
and practical criteria, which defined the recommendation either as actionable or non-actionable.  
In conclusion, this study provides strong and reliable pharmacoepidemiologic research results to 
be utilized in further studies and attempts to implement wide-scale pharmacogenetic testing in 
Finland.  
 
3.9 Study limitations 
 
This study also had some limitations. To be able to obtain data on the exact number of patients 
requiring dose adjustment or a change into an alternative drug, individual level genotype data would 
have been needed. This study utilized the population level phenotype frequency data previously 
published studies, which was utilized in calculating the estimated number of new drug users for 
each phenotype. In the future, individual level genotype data in biobanks might be utilized in 
pharmacoepidemiologic studies similar to this.  
Register data utilized did not reach up to the most recent years possible but only to 2014 for hospital 
admissions and to 2016 for drug purchases and mortality data. This might result in that the most 
recent treatment recommendations and common practises of prescribing were not able to be seen 
in the analyses. For example, prescribing of warfarin has decreased during the recent years 
according to the drug purchase database administered by KELA as the new oral anticoagulants 




according to results of this study warfarin was the fifth most frequently initiated drug.  If the latest 
drug purchase data would have been available, lesser warfarin initiations might have been seen. 
Regarding the drugs included into this study, antiemetic ondansetron and opioid-analgesic 
tramadol were not included. The ATC-code of ondansetron was not available in the existing drug 
purchase data. An update to the guideline on opioids and CYP2D6, OPRM1, and COMT was 
published at a time the drug identification was already conducted and addition of tramadol was not 
possible. It might have seen relatively low incidence rate for ondansetron in this patient cohort but 
the incidence rate for tramadol might have been significant based on relatively high DDD-number 
compared to other drugs of interest.    
It would have been interesting to see the total medication actively in use more individually. It was 
not possible to obtain individual medication list due to program coding technical reasons. However, 
in cumulative account of drug purchases it was seen that even 9 different drugs associated with 7 
different genes were purchased by a few patients during a 2-year follow-up. This indicates that 
patient cohort included polypharmacy patients, which have an overall greater risk for drug-drug 
interactions as well drug-gene interactions and a greater risk for adverse drug effects.  
This study was conducted by utilizing the selection of drugs marketed in Finland and the phenotype 
frequencies reported in the literature for the population of Finnish origin. This leads to a conclusion 
that the results are not applicable in other ethnicities or in other countries as such.  
The patients of this study cohort were discharged from either surgical or internal medicine unit, 
which caused a skewed study population in two ways. First, the sample consists of patients being 
hospitalized of various reasons, which might increase the average probability to initiate new drugs. 
Secondly, the data was originally collected for other study purposes and the hospital units in focus 
were determined to answer on other study hypotheses. Therefore, the results can neither be 
applied in the whole population level nor to represent all hospital-discharged patients. However, 
studying new drug initiations with this patient cohort can be expected to answer well in our study 
hypothesis and aim to discuss the relevance of pre-emptive pharmacogenetic testing for hospital 
patients in particular. Several new per oral drugs associated with relevant pharmacogenes are 







3.10 Future prospects 
 
There are several international projects aiming to implement pharmacogenetics into clinical 
practise, of which the EU-funded Ubiquitous Pharmacogenomics (U-PGx) project might be the most 
important. U-PGx focuses on bringing PGx based treatment optimization accessible for every 
European citizen in the near future (http://upgx.eu/). Moreover, the genomic data gained in Finnish 
FinnGen research project might be a valuable data source in biobank-based pharmacogenetic, 
pharmacoepidemiologic studies in Finland.  
To implement pre-emptive pharmacogenetic testing into clinical practise, clinicians are required to 
have better knowledge on how to interpret the PGx testing results. Educating health care 
professionals to utilize PGx information is crucial. Furthermore, precise and up-to-date electronic 
decision support tools are essential in implementing PGx data into clinical practise. An ideal would 
be that when prescribing, the system provides the doctor patient’s genotype data and a suggestion 
of suitable drug with a likely suitable dose. The system would propose the suitable drug not only 
based on genotype but also considering possible drug-drug interactions of other concomitant 
medication, as described by Liu et al. (2021) in their tutorial. In addition, van der Wouden et al. 
(2019) suggest, that the genotype data could also be accessible in electronic medical records in 
pharmacies, where the drug compatibilities and interactions are checked at dispensing. This leads 
to double-verification of the medication by several health care professionals and minimizing the risk 
of missing a drug-gene interaction. (Van der Wouden, C H et al., 2019) 
Currently, both the modern sequencing and information technology provide fast and reliable genetic 
testing results to be widely implemented. Costs related to the testing itself might not be the greatest 
barrier but the cost-effectiveness of the testing. It should be demonstrated in cost-effectivity studies 
that wide-scale implementation of pharmacogenetics in daily clinical practise would generate 
savings rather than costs for the society. In Finland, public resources are usually utilized in health 
care, although the trend is towards patients being interested in their genetic makeup themselves. 
Private companies providing easy homemade genetic tests have become popular and they should 
be seen as complimentary as long as they are validated and reliable.  
It should be concentrated to develop safe and easy-accessible data storage platform for 
pharmacogenetic testing results, which would facilitate the information to be utilized both in all 
health care providing units, including hospitals, health care centers and pharmacies both in public 
and private sectors. Pharmacogenetic aspects should be evaluated similarly as the other patient-
specific factors such as other concomitant medication, concomitant illnesses, age, other laboratory 




their unmedical need, it would be wise to most optimal way utilize the drugs already in the markets 
by carefully choosing the target patients. This was seen in a study of genotype-guided oral P2Y12 
drug selection for patients undergoing primary percutaneous coronary intervention. By genotyping 
and identifying patients at risk for bleeding, pharmacotherapy was successfully conducted. 
(Claassens et al., 2019) 
Attempts has been made to implement genome data and pharmacogenetics in Finnish health care 
in government strategies, such as in the National Genome Strategy and Report on medicinal data 
repository (http://julkaisut.valtioneuvosto.fi/handle/10024/74514; 
https://julkaisut.valtioneuvosto.fi/handle/10024/162655). The final decision for implementation is 
still lacking but hypothesis in favour of implementation has been widely proposed.  
 
3.11 The impact of these results in drug development  
 
It has been recognised that implementing pharmacogenetics into daily clinical practise requires 
multidisciplinary team work. (Just et al., 2019) One of the aspects this requires, is the involvement 
of pharmacogenetic studies already in the drug developmental phase. In the review by Liou et al., 
it is suggested that pharmacogenetic aspects would be included in both the target and dose 
selection, efficacy determination and in reviewing safety. (Liou et al., 2012) In Europe, the EMA 
has published guideline on Good Pharmacogenomic Practise for evaluating pharmacogenetic 
aspects in marketing authorisation applications of novel drugs 
(https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-
pharmacogenomic-practice-first-version_en.pdf). However, in an analysis by Maliepaard et al., it is 
stated that the drug developers and regulatory authorities should work together to be able to 
provide safe and effective pharmaceutical products for the patients, and that there is a need for 
harmonising the evaluation of the pharmacogenetic and pharmacokinetic interactions in marketing 
authorisation applications. (Maliepaard et al., 2020) An interesting perspective is utilizing 
pharmacogenetics in studies to find out whether drugs withdrawn from the markets due to major 
safety concerns might have a possibility to re-accessing the markets. (Zhang et al., 2012) 
Results of this study might not be directly applicable in the drug discovery and development phases. 
However, it is reasonable to consider pharmacogenetic aspects already from the beginning of drug 
discovery and development process as it is seen in this study that the pharmacogenetically relevant 
drugs are widely and commonly used and high variation occurs in phenotype frequencies leading 





3.12 Summary and conclusions 
 
Drugs having an actionable pharmacogenetic prescribing guideline are worldwide frequently used 
and clinically relevant. Genes affecting their metabolism and risk for adverse drug effects are highly 
polymorphic. Significant interethnic variation occurs in allele frequencies, which emphasizes the 
need for national studies concentrating locally relevant drugs and to which genes they are 
associated with. Currently, utilizing pharmacogenetic testing in prescribing is still limited mainly 
because of difficulties to interpret the testing results and apply them in common practise despite of 
major advances in PGx and several PGx testing panels becoming commercially available. 
However, it is known that risk for adverse drug effects and rehospitalization can be decreased by 
including patient’s genotype data into electronic decision support systems. Identification of patients 
clearly benefiting from pre-emptive pharmacogenetic testing to optimize personalized drug therapy 
will facilitate the implementation of PGx testing into common clinical practise in hospitals.  
Conclusively, this study alleviates the significance of pharmacogenetics in daily prescribing. 
Pharmacogenetically relevant drugs are common and frequently used, and majority of the patients 
have at least one pharmacogenetically relevant genetic variant present in their genome. As the 
general aim is to provide more personalized pharmacotherapy to the patients, pharmacogenetics 
should be considered as the normal practise in prescribing process. It is expected that in case cost-
effectiveness studies would turn out in favour of wide-scale (pre-emptive) pharmacogenetic testing, 
implementing pharmacogenetics into health care would begin. 
 
4. Materials and methods 
 
4.1 Reviewing the CPIC guidelines and determining the actionable study drugs 
and recommendation actionability 
 
A systematic and deep review of the drug prescribing guidelines compiled by the Clinical 
Pharmacogenetics Implementation Consortium (CPIC) was conducted and actionable drugs 
meeting eligibility criteria were identified. A drug was considered eligible when all following criteria 
were fulfilled; at least one actionable genotype was mentioned in the CPIC guidelines, a drug was 
marketed in Finland for a minimum time of 2 years during years 2008-2016, a drug was sold in 
community pharmacies by prescription, and its Anatomical Therapeutic Chemical (ATC) code was 




prescribing recommendations were considered; strong, moderate and optional. FimeaWeb -search 
tool provided by the Finnish Medicines Agency (FIMEA) and the drug database compiled by the 
Finnish Medical Society Duodecim were utilized to determine the ATC-codes for the drugs and their 
marketing status in Finland during the study years. 
(https://www.fimea.fi/web/en/databases_and_registeries/fimeaweb; 
https://www.duodecim.fi/tuotteet-ja-palvelut/terveysportti/laaketieto/) Identification was conducted 
by including all guidelines and their relevant updates to the known gene-drug interaction pairs 







Figure 8. Process of identifying actionable drugs. (CPIC = Clinical Pharmacogenetics 
Implementation Consortium, OTC = over the counter, ATC-code = The Anatomical Therapeutic 
Chemical code, KELA = the Social Insurance Institution of Finland)  
 
The CPIC prescribing recommendations were categorized as actionable or non-actionable 
regarding each metabolizing phenotype or allele carrying status. All relevant updates on 
recommendations, activity score calculations or interpreting the allele functions published by the 




were not possible at this point. However, the December 2020 update to the Guideline for Opioids 
and CYP2D6, OPRM1, and COMT was left unnoticed regarding opioids other than codeine 
because the drug identification and data analyses were already conducted earlier in October 2020, 
although the latest update to the CYP2D6 decreased function allele *10 activity score was adapted 
from the December 2020 update to the guideline for opioids. In determining the actionability, the 
FDA drug labels, PharmGKB-database for clinical annotations and general summaries for product 
characteristics were used as supplementary references in comparing the CPIC prescribing 
recommendations to the normal dosing strategy.  
In case the following criteria were fulfilled, the recommendation was classified as actionable; a clear 
recommendation to either increase or decrease the drug dose, a clear recommendation to choose 
another drug substance either with an entirely different metabolism route or with the same 
metabolism route but which has a smaller impact on the drug’s metabolism rate or a 
recommendation to a deviating dose titration scheme to achieve a therapeutic drug level. 
Recommendations concerning HLA-alleles HLA-A*31:01, HLA-B*15:02 and HLA-B*58:01 were 
considered as actionable for both homo- and heterozygous allele carries.  
 
All recommendations to prescribe a normal dose or a standard starting dose or recommendations 
to follow a normal dose titration scheme were considered as non-actionable even if the genotype 
was linked to abnormal metabolism but any adjustments from typical dosing strategy was not 
recommended. All recommendations for HLA-allele non-carriers were considered as non-
actionable. 
 
Only the main indication for each drug was considered when the recommendation actionability was 
determined leaving the possible additional indications unobserved, such as treatment of 
Helicobacter pylori infection or erosive esophagitis with proton pump inhibitors and neuropathic 
pain treatment with tricyclic antidepressants. In case the recommendation varied between different 
ethnic populations, recommendations for Europeans or other white ethnicities most close to Finnish 
population were included into the study. 
 
4.2. Defining the eligibility criteria for the patient cohort and data collection 
 
The main eligibility criterion was a hospital admission to either surgical, neurosurgical or internal 
medicine unit between 2008 and 2014, and the first hospital admission to either of the units of 




considered. Hospital stays in public hospitals providing specialist care in mainland Finland were 
observed. Only patients with an individual Finnish personal identity code were accepted. Patients 
treated in neurosurgical unit were combined with the group of patients treated in surgical unit. 
Surgical unit as a term will be used hereafter to refer the both units together. The study inclusion 
and exclusion criteria are listed in Table 5 below.  
 
Table 5. Study inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Inpatient period during the years 2008-2014 in either 
internal medicine or surgical (incl. neurosurgical unit) 
in specialized care in public hospitals in mainland 
Finland 
Patients with a generated personal identity code 
Patients in both genders Death occurring during the initiative hospital 
admission 
Age ≥ 18 years Age under 18 years 
 
4.3 Data collection from the individual level register data 
 
The register data utilized in this study was collected for an epidemiological research purposes and 
was already available during the time of initiation of the thesis project. Pseudonymised, individual 
level data from three different national registers were used in the current study. The register data 
consisted of data from the Care Register for Health Care in Finland (CRHF, fin. HILMO, 
Hoitoilmoitusjärjestelmä). The CRHF is administered by the Finnish Institute for Health and Welfare 
(THL), and collects information of all hospital admissions in Finland, including patient specific 
details, diagnoses, procedures and interventions during inpatient period, dates for admission and 
discharging and a reason for seeking care.  (https://thl.fi/en/web/thlfi-en/statistics/information-on-
statistics/register-descriptions/care-register-for-health-care) Moreover, data from the nationwide 
prescription register administered by the Social Insurance Institution on Finland (KELA) was 
utilized, which includes drug purchase data and purchase dates with drug-specific Anatomical 
Therapeutic Chemical codes (ATC codes). Additionally, mortality data provided by the Statistics 
Finland was utilized. Based on the inclusion criteria, hospital admission data between 2008 and 
2014, drug purchase data between 2008 and 2016 and mortality data between 2008 and 2016 was 




Data manipulation and individual level analyses were conducted with the SAS System for Windows, 
version 9.4 (SAS Institute Inc., Cary, NC, USA) by the study statistician who had been granted 
permissions to handle the pseudonymized individual level data. The study statistician performed 
the data manipulation and individual level analyses based on the criteria defined by the other 
research group members. According to the permissions, other research group members were only 
allowed to receive aggregate level anonymous data for the data analyses.   
The hospital admission date was considered as the index date to begin the follow-up time as 
defined above in section 4.2. In the individual level analyses, each patient was followed until the 
end of year 2016 or until death, whichever came first. However, death occurring already during the 
hospital stay was an exclusion criterion.  
 
Active drug use of the study drugs was determined for each patient 180 days before entering the 
study to describe the prevalence of the drug use at the moment of hospital admission. Prevalence 
rates were calculated for each drug and for each gene separately. New post-discharge drug 
initiations of the study drugs were recorded to describe the incidence of drug purchases. Incidence 
rates were calculated for each drug and associated genes. A drug was considered new if the patient 
had not been using it 365 days before entering the study. The primary outcome was the first post-
discharge drug purchase of any of the study drugs. Additionally, the cumulative account of different 
post-discharge drug purchases of the drugs of interest was determined for each patient at 1 and 2 
years after the hospital discharge. Both the patient specific number of different post-discharge-
initiated study drugs and a number of genes associated to the drug purchases were calculated. 
Long-term post-discharge drug purchases were analysed with and visualised in the Microsoft Excel 
(version 2102).  
 
4.4. Combining Finnish phenotype frequencies with the drug incidence data  
 
Finnish phenotype frequencies for each different drug metabolizing phenotypes associated with 
the genes of interest were determined by utilizing previously published studies and the SISU-
database, which is a search engine on sequence variants in Finns (http://www.sisuproject.fi/). The 
phenotype frequencies were combined with the drug incidence rates to predict the phenotype-
specific number of new drug users in 2-year follow-up. Only frequencies of people with Finnish 
heritage were accepted due to unique Finnish gene heritage, excluding phenotype frequencies of 




Both the prevalence and the incidence rates, as well as the predicted number of new drug initiations 
for each phenotype were proportionated to the total number of study participants to reason the 
significance in the total cohort level.  
 
4.5. Analysing the explanatory factors behind drug initiations with Cox 
proportional-hazards model 
 
Long-term drug purchase data was analysed with the Cox proportional-hazards model adjusted for 
type of the hospital unit using SAS System for Windows, version 9.4 (SAS Institute Inc., Cary, NC, 
USA) by the study statistician. The purpose was to examine the differences in post-discharge drug 
purchases between patients discharged from surgical unit with patients discharged from internal 
medicine unit. The Cox analysis was conducted with patients without previous drug purchases of 
the drugs of interest associated with the genes. Death occurring during the follow-up time led to 
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ADR  adverse drug reaction 
AS  Activity Score 
ATC  Anatomical Therapeutic Chemical 
CPIC  the Clinical Pharmacogenetics Implementation Consortium 
CRHF  Care Register for Health Care 
CYP  cytochrome P450 
DPD  dihydropyrimidine dehydrogenase (enzyme)  
DPWG  The Dutch Pharmacogenetics Working Group 
DPYD  dihydropyrimidine dehydrogenase (gene) 
EM  extensive metabolizer 
EMA  the European Medicines Agency 
FDA  the United States Food and Drug Administration 
FIMEA  the Finnish Medicines Agency Fimea 
HLA  human leukocyte antigen 
IM  intermediate metabolizer 
KELA  the Social Insurance Institution of Finland 
NM  normal metabolizer 
NUDT15  Nudix Hydrolase 15 gene or enzyme 
OATP1B1  Organic anion transporting polypeptide 1B1 protein 
PGx  interchangeably used for pharmacogenetics (PGt)  
and pharmacogenomics 
PM  poor metabolizer 
RM  rapid metabolizer 
SJS  Stevens-Johnsons Syndrome 
SLCO1B1  Solute Carrier Organic Anion Transporter Family Member 1B1 gene 
TEN  toxic epidermal necrolysis 
THL  the Finnish Institute for Health and Welfare 
TPMT  thiopurine S-methyltransferase gene or enzyme 
UM  ultrarapid metabolizer 
U-PGx  Ubiquitous Pharmacogenomics consortium 
VKORC1  Vitamin K Epoxide Reductase Complex Subunit 1 gene, 
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Drug Gene Phenotype CPIC recommendation 
 
Mercaptopurine TPMT NM Lower concentrations of TGN metabolites Normal 
risk of thiopurine-related leukopenia, neutropenia, 




Moderate to high concentrations of TGN 
metabolites. Increased risk of thiopurine-related 
leukopenia, neutropenia, myelosuppression. 
Reduced starting doses. 
  
PM Extremely high concentrations of TGN metabolites; 
fatal toxicity possible without dose decrease. 
Greatly increased risk of thiopurine-related 
leukopenia, neutropenia, myelosuppression. 
Reduced starting doses or alternative drug. 
Azathioprine TPMT NM Lower concentrations of TGN metabolites. Normal 
risk of thiopurine-related leukopenia, neutropenia, 




Moderate to high concentrations of TGN 
metabolites. Increased risk of thiopurine-related 
leukopenia, neutropenia, myelosuppression. 
Reduced starting doses.   
  
PM Extremely high concentrations of TGN metabolites; 
fatal toxicity possible without dose decrease. 
Greatly increased risk of thiopurine-related 
leukopenia, neutropenia, myelosuppression. 
Reduced doses or alternative drug.  
Thioguanine TPMT NM Lower concentrations of TGN metabolites. Normal 
risk of thiopurine-related leukopenia, neutropenia, 




Moderate to high concentrations of TGN 
metabolites. Increased risk of thiopurine-related 
leukopenia, neutropenia, myelosuppression. 
Reduced starting doses.  
  
PM Extremely high concentrations of TGN metabolites; 
fatal toxicity possible without dose decrease. 
Greatly increased risk of thiopurine-related 
leukopenia, neutropenia, myelosuppression. 










NM Normal risk of thiopurine-related leukopenia, 
neutropenia, myelosuppression, normal starting 
dose, dose adjustments in at least 2 weeks 





Increased risk of thiopurine-related leukopenia, 
neutropenia, myelosuppression. Reduced starting 
doses.  
  
PM Greatly increased risk of thiopurine-related 
leukopenia, neutropenia, myelosuppression. 
Reduced starting doses or alternative drug.  
Azathioprine NUDT
15 
NM Normal risk of thiopurine-related leukopenia, 





Increased risk of thiopurine-related leukopenia, 
neutropenia, myelosuppression. Reduced starting 
doses. 
  
PM Greatly increased risk of thiopurine-related 
leukopenia, neutropenia, myelosuppression. 
Reduced starting doses or alternative drug.  
Thioguanine NUDT
15 
NM Normal risk of thiopurine-related leukopenia, 
neutropenia, myelosuppression. Normal starting 




Increased risk of thiopurine-related leukopenia, 
neutropenia, myelosuppression. Reduced starting 
doses.   
  
PM Greatly increased risk of thiopurine-related 
leukopenia, neutropenia, myelosuppression. 









intermediate myopathy risk, lower starting dose or 
alternative statin, routine monitoring of CK levels  
 
  
low function high myopathy risk, lower starting dose or 
alternative statin, routine monitoring of CK levels 
 
 
Capecitabine DPYD NM (AS 2) Two copies of normal function DPYD alleles. 
Normal DPD activity and “normal” risk for 
fluoropyrimidine toxicity, normal dosage 
  
IM (AS 1.5) One normal function and one decreased function 
allele. 30-70% decreased DPD activity and 
increased risk for severe or even fatal drug toxicity, 





IM (AS 1) Either one normal and one no function allele OR 
two decreased function alleles. 30-70% decreased 
DPD activity and increased risk for severe or even 
fatal drug toxicity. 50% dose reduction from the 
standard starting dose. 
  
PM (AS 0.5) One copy of a decreased function allele and one 
copy of a no function allele. DPD deficiency and 
increased risk for severe or even fatal drug toxicity, 
avoid use of capecitabine, strongly reduced starting 
doses (<25% of the normal dose) if alternative 
therapies are not suitable 
Drug Gene Phenotype CPIC recommendation 
 
  
PM (AS 0) Two copies of no function alleles of the DPYD 
gene. Complete DPD deficiency and increased risk 
for severe or even fatal drug toxicity, avoid use of 








"normal", non-mutant carrier, dose according to 






Dose according to validated pharmacogenetic 






Dose according to validated pharmacogenetic 














A/G or A/A 
Dose according to validated pharmacogenetic 





Normal metabolism, dose according to validated 
pharmacogenetic algorithms 
  Non-African: 
CYP4F2*3  
Calculate dose with a validated pharmacogenetic 













normal metabolism, dose according to validated 
pharmacogenetic algorithms 
  







decreased metabolism leading to dose decrease, 
dose according to validated pharmacogenetic 
algorithms 
  




3 or *3/*3  
decreased metabolism leading to dose decrease, 




*5, *6, *8 or 
*11  
Decrease calculated dose by 15-30% per variant 

















*6, *8 or *11  
Decrease calculated dose by 15-30% per variant 








Increased risk of phenytoin-induced SJS/TEN, 
phenytoin contraindicated, avoid use of 


















Patient has one normal function allele plus one 
decreased function allele. Slightly reduced 
phenytoin metabolism. No adjustments needed 







Patient has one normal function allele plus one no 
function allele OR two decreased function alleles. 
Reduced phenytoin metabolism, higher plasma 
concentrations increasing the probability to 
toxicities. Use approximately 25% less than typical 
maintenance dose.  
  
CYP2C9 
PM, AS 0.5 
Patient has one no function allele and one 
decreased function allele, reduced phenytoin 
metabolism, higher plasma concentrations 
increasing the probability to toxicities. Use 




PM, AS 0 
Patient has two no function alleles, reduced 
phenytoin metabolism, higher plasma 
concentrations increasing the probability to 
toxicities. Use approximately 50% less than typical 
maintenance dose. 









Allopurinol contraindicated due to significantly 
















Greater risk for carbamazepine-induced reactions 
(SJS/TEN), carbamazepine contraindicated, use 






Normal risk of carbamazepine-induced reactions 








Greater risk of carbamazepine-induced reactions 
(SJS/TEN, DRESS and MPE), carbamazepine 







Normal risk of carbamazepine-induced reactions 













Greater risk of oxcarbazepine-induced reactions 
(SJS/TEN), oxcarbazepine contraindicated, use 







Normal risk of oxcarbazepine-induced reactions 






Extensive metabolizer, lower drug concentration, 





Intermediate metabolizer, lower drug concentration, 







Poor metabolizer = normal metabolism, drug 
initiation with standard recommended dose 
Codeine CYP2
D6 
UM (AS > 
2.25) 
Increased formation of morphine leading to higher 
risk of toxicity. Avoid codeine use because of 
potential for serious toxicity. If opioid use is 





Expected morphine formation. Use codeine label 
recommended age- or weight-specific dosing. 
  
IM (AS >0 - 
<1.25) 
Reduced morphine formation. Use codeine label 
recommended age- or weight-specific dosing. If no 
response and opioid use is warranted, consider a 
non-tramadol opioid. 
  
PM (AS 0) Greatly reduced morphine formation leading to 
diminished analgesia. Avoid codeine use because 
of possibility of diminished analgesia. If opioid use 





Likely inadequate serum concentrations for 
intended effect in standard dosing, normal dose 





normal metabolism, normal dose titration to 
therapeutic level 
  
IM (AS 1) patient may not achieve adequate serum 
concentrations for the intended effect at standard 




increased risk of a atomoxetine-related adverse 
events. Slower dose titration to therapeutic level.  
  
PM (AS 0) significantly decreased atomoxetine metabolism 
leading to higher concentrations. Slower dose 
















normal metabolism, normal starting doses 
  
IM (AS >0 - 
<1.25) 
reduced metabolism, higher plasma concentrations 
may increase the probability of side effects, normal 
starting doses 
  
PM (AS 0) greatly reduced metabolism, higher plasma 
concentrations may increase the probability of side 
effects, consider a 25-50% reduction of 





increased metabolism, low plasma concentration 






normal metabolism, normal starting dose 
  
IM (AS >0 - 
<1.25) 
reduced metabolism, higher plasma concentration 
may lead to side effects, normal starting dose 
  
PM (AS 0) greatly reduced metabolism, higher plasma 
concentration may lead to side effects, alternative 








Increased metabolism, lower plasma 
concentrations may lead to therapy failure, avoid 
TCA use due to potential lack of efficacy, consider 
an alternative drug, TCAs to consider only with 





normal metabolism, normal starting doses 
  
IM (AS >0 - 
<1.25) 
reduced metabolism, higher plasma concentrations 
may lead to side effects, consider a 25% reduction 
in starting dose 
  
PM (AS 0) greatly reduced metabolism, higher plasma 
concentrations may lead to side effects, avoid TCA 
use due to potential lack of efficacy, consider an 
alternative drug, TCAs to consider with 50% 








UM and RM Increased metabolism of TCAs leading to sub-
optimal drug response and side effects, avoid 
TCAs, consider an alternative drug, TCAs to be 
considered only with drug monitoring 
  
NM normal metabolism, normal starting doses 
  
IM reduced metabolism, drug initiation with normal 
starting doses 
  
PM greatly reduced metabolism of TCAs leading to 
sub-optimal drug response and side effects, avoid 
TCAs, consider an alternative drug, TCAs to be 
considered only with 50% reduction of 






Increased metabolism, lower plasma 
concentrations may lead to therapy failure, avoid 
TCA use due to potential lack of efficacy, consider 
an alternative drug, TCAs to consider only with 





normal metabolism, normal starting doses 
  
IM (AS >0 - 
<1.25) 
reduced metabolism, higher plasma concentrations 
may lead to side effects, consider a 25% reduction 
in starting dose, drug monitoring to guide dose 
adjustments 
  
PM (AS 0) greatly reduced metabolism, higher plasma 
concentrations may lead to side effects, avoid TCA 
use due to potential lack of efficacy, consider an 
alternative drug, TCAs to consider with 50% 
reduction in starting doses, drug monitoring 
Clomipramine CYP2
C19 
UM and RM Increased metabolism of TCAs leading to sub-
optimal drug response and side effects, avoid 
TCAs, consider an alternative drug, TCAs to be 
considered only with drug monitoring to guide dose 
adjustments 
  
NM normal metabolism, normal starting doses 
  
IM reduced metabolism, drug initiation with normal 
starting doses 
  
PM greatly reduced metabolism of TCAs leading to 
sub-optimal drug response and side effects, avoid 
TCAs, consider an alternative drug, TCAs to be 
considered only with 50% reduction of 
recommended starting doses and therapeutic drug 










Increased metabolism, lower plasma 
concentrations may lead to therapy failure, avoid 
TCA use due to potential lack of efficacy, consider 
an alternative drug, TCAs to consider only with 





normal metabolism, normal starting doses 
  
IM (AS >0 - 
<1.25) 
reduced metabolism, higher plasma concentrations 
may lead to side effects, consider a 25% reduction 
in starting dose, drug monitoring to guide dose 
adjustments 
  
PM (AS 0) greatly reduced metabolism, higher plasma 
concentrations may lead to side effects, avoid TCA 
use due to potential lack of efficacy, consider an 
alternative drug, TCAs to consider with 50% 
reduction in starting doses, drug monitoring 
Doxepine CYP2
C19 
UM and RM Increased metabolism of TCAs leading to sub-
optimal drug response and side effects, avoid 
TCAs, consider an alternative drug, TCAs to be 
considered only with drug monitoring to guide dose 
adjustments 
  
NM normal metabolism, normal starting doses 
  
IM reduced metabolism, drug initiation with normal 
starting doses 
  
PM greatly reduced metabolism of TCAs leading to 
sub-optimal drug response and side effects, avoid 
TCAs, consider an alternative drug, TCAs to be 
considered only with 50% reduction of 
recommended starting doses and therapeutic drug 





Increased metabolism, lower plasma 
concentrations may lead to therapy failure, avoid 
TCA use due to potential lack of efficacy, consider 
an alternative drug, TCAs to consider only with 





normal metabolism, normal starting doses 
  
IM (AS >0 - 
<1.25) 
reduced metabolism, higher plasma concentrations 
may lead to side effects, consider a 25% reduction 
in starting dose, drug monitoring to guide dose 
adjustments 
  
PM (AS 0) greatly reduced metabolism, higher plasma 
concentrations may lead to side effects, avoid TCA 
use due to potential lack of efficacy, consider an 
alternative drug, TCAs to consider with 50% 










Increased metabolism, lower plasma 
concentrations may lead to therapy failure, avoid 
TCA use due to potential lack of efficacy, consider 
an alternative drug, TCAs to consider only with 





normal metabolism, normal starting doses 
  
IM (AS >0 - 
<1.25) 
reduced metabolism, higher plasma concentrations 
may lead to side effects, consider a 25% reduction 
in starting dose, drug monitoring to guide dose 
adjustments 
  
PM (AS 0) greatly reduced metabolism, higher plasma 
concentrations may lead to side effects, avoid TCA 
use due to potential lack of efficacy, consider an 
alternative drug, TCAs to consider with 50% 
reduction in starting doses, drug monitoring 
Trimipramine CYP2
C19 
UM and RM Increased metabolism of TCAs leading to sub-
optimal drug response and side effects, avoid 
TCAs, consider an alternative drug, TCAs to be 
considered only with drug monitoring to guide dose 
adjustments 
  
NM normal metabolism, normal starting doses 
  
IM reduced metabolism, drug initiation with normal 
starting doses 
  
PM greatly reduced metabolism of TCAs leading to 
sub-optimal drug response and side effects, avoid 
TCAs, consider an alternative drug, TCAs to be 
considered only with 50% reduction of 
recommended starting doses and therapeutic drug 
monitoring to guide dose adjustments 
Citalopram CYP2
C19 
UM increased metabolism, lower plasma 
concentrations may lead to therapy failure, 
consider an alternative drug  
  
EM normal metabolism, normal starting doses 
  
IM reduced metabolism, normal starting doses 
  
PM greatly reduced metabolism, higher plasma 
concentrations may lead to side effects, consider a 
50% reduced starting dose, titrate to response or 








UM increased metabolism, lower plasma 
concentrations may lead to therapy failure, 
consider an alternative drug  
  
EM normal metabolism, normal starting doses 
  
IM reduced metabolism, normal starting doses 
  
PM greatly reduced metabolism, higher plasma 
concentrations may lead to side effects, consider a 
50% reduced starting dose, titrate to response or 
choose an alternative drug 
Sertraline CYP2
C19 
UM increased metabolism, drug initiation with a 
recommended starting dose 
  
EM normal metabolism, normal starting doses 
  
IM reduced metabolism, normal starting doses 
  
PM greatly reduced metabolism, higher plasma 
concentrations may lead to side effects, consider a 
50% reduced starting dose, titrate to response or 
choose an alternative drug  
Tamoxifen CYP2
D6 
UM (AS > 
2.25) 












Lower than normal CYP2D6 activity and increased 
risk of a poor tamoxifen response. Consider an 
alternative drug or use a higher tamoxifen dose. 
  
PM (AS 0) Decreased tamoxifen metabolism, an alternative 




NM (AS 2) normal metabolism, normal starting doses 
  
IM (AS 1.5) mildly reduced metabolism, slightly higher risk for 
adverse events, normal starting doses 
  
IM (AS 1.0) moderately reduced metabolism, higher plasma 
concentrations leading to increased risk for 
toxicities, therapy initiation with lowest possible 
dose 
  
PM (AS 0 - 
0.5) 
significantly reduced metabolism and prolonged 
half-life, higher plasma concentrations leading to 
increased risk for toxicities, therapy initiation with 








NM (AS 2) normal metabolism, normal starting doses 
  
IM (AS 1.5) mildly reduced metabolism, slightly higher risk for 
adverse events, normal starting doses  
  
IM (AS 1.0) moderately reduced metabolism, higher plasma 
concentrations leading to increased risk for 
toxicities, therapy initiation with lowest possible 
dose 
  
PM (AS 0 - 
0.5) 
significantly reduced metabolism and prolonged 
half-life, higher plasma concentrations leading to 
increased risk for toxicities, therapy initiation with 
lower dose or an alternative drug 
Meloxicam CYP2
C9 
NM (AS 2) normal metabolism, normal starting doses 
  
IM (AS 1.5) mildly reduced metabolism, normal starting doses 
  
IM (AS 1.0) moderately reduced metabolism, higher plasma 
concentrations leading to increased risk for 
toxicities, therapy initiation with lower dose or an 
alternative drug  
  
PM (AS 0 - 
0.5) 
significantly reduced metabolism and prolonged 
half-life, higher plasma concentrations leading to 
increased risk for toxicities, choose alternative drug 
Piroxicam CYP2
C9  
NM Normal metabolism,              
normal starting doses 
  IM (AS 1.5)       Mildly reduced metabolism, normal starting doses 
   
 
IM (AS 1.0) Moderately reduced metabolism, higher plasma 
concentrations leading to increased risk for 
toxicities, choose alternative drug 
    PM (AS 0 - 
0.5) 
Significantly reduced metabolism and prolonged 
half-life, higher plasma concentrations leading to 
increased risk for toxicities, choose alternative drug 
Omeprazole CYP2
C19 
UM decreased plasma concentrations, risk for 
therapeutic failure, increase starting daily dose by 
100% 
  
RM decreased plasma concentrations, risk for 
therapeutic failure, therapy initiation with normal 
dose but consider increasing dose by 50-100% in 
treatment of H. pylori and erosive esophagitis 
  
NM normal metabolism, normal starting doses, but 
consider increasing starting dose by 50-100% in 
treatment of H. pylori and erosive esophagitis 
  
IM and likely 
IM 
increased plasma concentration, likely increased 
efficacy and potentially toxicity, initiation with 
normal doses, in chronic treatment (>12 weeks) 







increased plasma concentration, likely increased 
efficacy and potentially toxicity, initiation with 
normal doses, in chronic treatment (>12 weeks) 
50% reduction in daily dose to be considered 




UM decreased plasma concentrations, risk for 
therapeutic failure, increase starting daily dose by 
100% 
  
RM decreased plasma concentrations, risk for 
therapeutic failure, therapy initiation with normal 
dose but consider increasing starting dose by 50-
100% in treatment of H. pylori and erosive 
esophagitis 
  
NM normal metabolism, normal starting doses, but 
consider increasing starting dose by 50-100% in 
treatment of H. pylori and erosive esophagitis 
  
IM and likely 
IM 
increased plasma concentration, likely increased 
efficacy and potentially toxicity, initiation with 
normal doses, in chronic treatment (>12 weeks) 




increased plasma concentration, likely increased 
efficacy and potentially toxicity, initiation with 
normal doses, in chronic treatment (>12 weeks) 
50% reduction in daily dose to be considered 
Pantoprazole CYP2
C19 
UM decreased plasma concentrations, risk for 
therapeutic failure, increase starting daily dose by 
100% 
  
RM decreased plasma concentrations, risk for 
therapeutic failure, therapy initiation with normal 
dose but consider increasing starting dose by 50-
100% in treatment of H. pylori and erosive 
esophagitis 
  
NM normal metabolism, normal starting doses, but 
consider increasing starting dose by 50-100% in 
treatment of H. pylori and erosive esophagitis 
  
IM and likely 
IM 
increased plasma concentration, likely increased 
efficacy and potentially toxicity, initiation with 
normal doses, in chronic treatment (>12 weeks) 




increased plasma concentration, likely increased 
efficacy and potentially toxicity, initiation with 
normal doses, in chronic treatment (>12 weeks) 













UM subtherapeutic concentrations, risk for treatment 
failure, alternative antifungal treatment 
recommended 
  
RM subtherapeutic concentrations, risk for treatment 
failure, alternative antifungal treatment 
recommended 
  
NM normal metabolism, normal drug concentration, 
initiate therapy with recommended standard dosing 
  
IM higher drug concentration, initiate therapy with 
recommended standard dosing 
  
PM higher concentration, risk for adverse events, 
alternative antifungal treatment recommended, 
voriconazole to be considered only with lower 
dosing and careful monitoring 
Clopidogrel CYP2
C19 
UM increased platelet inhibition, decreased residual 
platelet aggregation, normal doses 
  
EM normal platelet inhibition, normal residual platelet 
aggregation, normal doses 
  
IM reduced platelet inhibition, increased residual 
platelet aggregation, increased risk for adverse 
cardiovascular events, alternative antiplatelet 
therapy recommended 
  
PM significantly reduced platelet inhibition, increased 
residual platelet aggregation, increased risk for 
adverse cardiovascular events, alternative 
antiplatelet therapy recommended 
